<!DOCTYPE html>
<!-- 
INFORMATION ARCHITECTURE PLAN

Mobile layout:
- Sticky top header with title, search bar, and hamburger menu
- Hamburger opens full-screen TOC drawer
- Collapsible accordion sections
- Persistent "Back to top" FAB (bottom-right)
- Thumb-friendly tap targets (>=44px)
- Toggle bar: [Evidence] [Implementation] [Quick View]

Tablet/Desktop layout (>=768px):
- Left sticky sidebar (TOC, 260px) + right scrollable main content
- Two-column recommendation cards
- TOC highlights active section on scroll
-->
<html lang="en-GB">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>ASH/ISTH 2024 Updated Guidelines ‚Äî VTE in Paediatric Patients</title>
<style>
@import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700;800;900&display=swap');

/* ===== DESIGN TOKENS ===== */
:root {
  /* Core palette ‚Äî deep clinical navy + blood red accent */
  --clr-primary: #0f2d52;
  --clr-primary-hover: #1a3f6f;
  --clr-primary-light: #e8f0fb;
  --clr-accent: #b91c1c;
  --clr-accent-light: #fee2e2;
  --clr-accent2: #d97706;
  --clr-accent2-light: #fef3c7;
  --clr-success: #15803d;
  --clr-success-light: #dcfce7;

  /* Category colours */
  --clr-purple: #7c3aed;
  --clr-purple-light: #ede9fe;
  --clr-teal: #0f766e;
  --clr-teal-light: #ccfbf1;
  --clr-brown: #92400e;
  --clr-brown-light: #fef3c7;
  --clr-steel: #1d4ed8;
  --clr-steel-light: #dbeafe;
  --clr-crimson: #be123c;
  --clr-crimson-light: #ffe4e6;

  /* Surfaces */
  --clr-bg: #f0f4f8;
  --clr-bg-2: #e8ecf2;
  --clr-card: #ffffff;
  --clr-card-hover: #fafbff;
  --clr-border: #d1d9e6;
  --clr-border-light: #e8ecf4;

  /* Text */
  --clr-text: #1a202c;
  --clr-text-muted: #4a5568;
  --clr-text-subtle: #718096;

  /* Typography */
  --font-stack: 'Inter', 'Segoe UI', system-ui, -apple-system, sans-serif;
  --font-mono: 'JetBrains Mono', 'Fira Code', monospace;

  /* Spacing */
  --sidebar-width: 272px;
  --header-height: 64px;
  --togglebar-height: 48px;
  --radius-sm: 6px;
  --radius: 12px;
  --radius-lg: 16px;
  --radius-xl: 20px;

  /* Shadows ‚Äî layered elevation system */
  --shadow-xs: 0 1px 2px rgba(15,45,82,0.04);
  --shadow-sm: 0 1px 4px rgba(15,45,82,0.06), 0 2px 8px rgba(15,45,82,0.04);
  --shadow: 0 2px 8px rgba(15,45,82,0.08), 0 4px 16px rgba(15,45,82,0.04);
  --shadow-md: 0 4px 16px rgba(15,45,82,0.10), 0 8px 32px rgba(15,45,82,0.06);
  --shadow-lg: 0 8px 32px rgba(15,45,82,0.14), 0 16px 48px rgba(15,45,82,0.08);
  --shadow-xl: 0 16px 48px rgba(15,45,82,0.18), 0 32px 64px rgba(15,45,82,0.10);

  /* Transitions */
  --transition-fast: 0.15s cubic-bezier(0.4, 0, 0.2, 1);
  --transition: 0.25s cubic-bezier(0.4, 0, 0.2, 1);
  --transition-slow: 0.4s cubic-bezier(0.4, 0, 0.2, 1);

  /* Legacy aliases */
  --radius-old: var(--radius);
  --shadow-old: var(--shadow);
  --shadow-lg-old: var(--shadow-lg);
}

/* ===== DARK MODE ===== */
[data-theme="dark"] {
  --clr-primary: #3b82f6;
  --clr-primary-hover: #60a5fa;
  --clr-primary-light: #1e3a5f;
  --clr-accent: #f87171;
  --clr-accent-light: #3b1212;
  --clr-accent2: #fbbf24;
  --clr-accent2-light: #3b2700;
  --clr-success: #34d399;
  --clr-success-light: #052e16;
  --clr-purple: #a78bfa;
  --clr-purple-light: #2e1065;
  --clr-teal: #2dd4bf;
  --clr-teal-light: #042f2e;
  --clr-steel: #60a5fa;
  --clr-steel-light: #1e3a5f;
  --clr-crimson: #f87171;
  --clr-crimson-light: #3b1212;
  --clr-bg: #0d1117;
  --clr-bg-2: #161b22;
  --clr-card: #161b22;
  --clr-card-hover: #1c2230;
  --clr-border: #30363d;
  --clr-border-light: #21262d;
  --clr-text: #e6edf3;
  --clr-text-muted: #8b949e;
  --clr-text-subtle: #656d76;
  --shadow-xs: 0 1px 2px rgba(0,0,0,0.3);
  --shadow-sm: 0 1px 4px rgba(0,0,0,0.4), 0 2px 8px rgba(0,0,0,0.2);
  --shadow: 0 2px 8px rgba(0,0,0,0.4), 0 4px 16px rgba(0,0,0,0.2);
  --shadow-md: 0 4px 16px rgba(0,0,0,0.5), 0 8px 32px rgba(0,0,0,0.3);
  --shadow-lg: 0 8px 32px rgba(0,0,0,0.6), 0 16px 48px rgba(0,0,0,0.4);
  --shadow-xl: 0 16px 48px rgba(0,0,0,0.7), 0 32px 64px rgba(0,0,0,0.5);
}
[data-theme="dark"] body {
  background: var(--clr-bg);
  color: var(--clr-text);
}
[data-theme="dark"] #site-header {
  background: linear-gradient(135deg, #0d1117 0%, #161b22 60%, #1c2230 100%);
  box-shadow: 0 4px 24px rgba(0,0,0,0.6), 0 1px 0 rgba(255,255,255,0.04) inset;
}
[data-theme="dark"] #toggle-bar {
  background: rgba(22,27,34,0.95);
  border-bottom-color: var(--clr-border);
}
[data-theme="dark"] #toggle-bar-pill {
  background: rgba(22,27,34,0.98);
  border-color: var(--clr-border);
  color: var(--clr-text-subtle);
}
[data-theme="dark"] #sidebar {
  background: var(--clr-card);
  border-right-color: var(--clr-border);
}
[data-theme="dark"] .rec-card {
  background: var(--clr-card);
  border-color: var(--clr-border);
}
[data-theme="dark"] .rec-header {
  background: var(--clr-card-hover);
}
[data-theme="dark"] .data-table thead th {
  background: linear-gradient(135deg, #1c2230, #21262d);
  color: var(--clr-text);
}
[data-theme="dark"] .data-table tbody tr:nth-child(even) {
  background: rgba(255,255,255,0.03);
}
[data-theme="dark"] .data-table tbody tr:hover {
  background: rgba(255,255,255,0.06);
}
[data-theme="dark"] .trial-card {
  background: linear-gradient(135deg, #161b22, #1c2230);
  border-color: var(--clr-border);
}
[data-theme="dark"] .trial-card::before {
  background: linear-gradient(135deg, #3b82f6, #60a5fa);
}
[data-theme="dark"] .situation-card {
  background: var(--clr-card);
  border-color: var(--clr-border);
}
[data-theme="dark"] .situation-header {
  background: var(--clr-card-hover);
}
[data-theme="dark"] .callout {
  border-left-width: 3px;
}
[data-theme="dark"] .callout.danger {
  background: rgba(59,18,18,0.5);
}
[data-theme="dark"] .callout.warning {
  background: rgba(59,39,0,0.5);
}
[data-theme="dark"] .callout.info {
  background: rgba(30,58,95,0.5);
}
[data-theme="dark"] .callout.success {
  background: rgba(5,46,22,0.5);
}
[data-theme="dark"] .panel-tabs {
  background: var(--clr-bg-2);
  border-bottom-color: var(--clr-border);
}
[data-theme="dark"] .panel-tab {
  color: var(--clr-text-muted);
}
[data-theme="dark"] .panel-tab.active {
  color: var(--clr-primary);
  background: var(--clr-card);
}
[data-theme="dark"] .hero-section {
  background: linear-gradient(135deg, #0d1117 0%, #161b22 50%, #0d2237 100%);
}
[data-theme="dark"] .section-title {
  color: var(--clr-text);
}
[data-theme="dark"] .table2-group {
  background: var(--clr-card);
  border-color: var(--clr-border);
}
[data-theme="dark"] .table2-group-header {
  background: linear-gradient(135deg, #1c2230, #21262d);
  color: var(--clr-text);
}
[data-theme="dark"] .table2-item {
  border-bottom-color: var(--clr-border-light);
}
[data-theme="dark"] #disclaimer {
  background: rgba(22,27,34,0.8);
  border-color: var(--clr-border);
  color: var(--clr-text-muted);
}
[data-theme="dark"] #back-to-top {
  background: #3b82f6;
}
[data-theme="dark"] .toggle-btn {
  background: var(--clr-bg-2);
  border-color: var(--clr-border);
  color: var(--clr-text-muted);
}
[data-theme="dark"] .toggle-btn:hover:not(.active) {
  background: var(--clr-primary-light);
  color: var(--clr-primary);
  border-color: var(--clr-primary);
}
[data-theme="dark"] .overview-card {
  background: var(--clr-card);
  border-color: var(--clr-border);
}
[data-theme="dark"] .grade-legend-item {
  background: var(--clr-card-hover);
  border-color: var(--clr-border);
}


/* ===== RESET & BASE ===== */
*, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
html {
  scroll-behavior: smooth;
  font-size: 16px;
  scrollbar-width: thin;
  scrollbar-color: var(--clr-border) transparent;
  /* Offset anchor scroll so sticky header + toggle bar never cover the target */
  scroll-padding-top: calc(var(--header-height) + var(--togglebar-height) + 12px);
}
html::-webkit-scrollbar { width: 6px; }
html::-webkit-scrollbar-thumb { background: var(--clr-border); border-radius: 4px; }
html::-webkit-scrollbar-thumb:hover { background: #94a3b8; }

body {
  font-family: var(--font-stack);
  background: var(--clr-bg);
  color: var(--clr-text);
  line-height: 1.65;
  min-height: 100vh;
  font-feature-settings: 'kern' 1, 'liga' 1, 'calt' 1;
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}
a { color: var(--clr-primary); text-decoration: none; }
a:hover { text-decoration: underline; }
img { max-width: 100%; }
button { font-family: inherit; cursor: pointer; border: none; }
ul, ol { padding-left: 1.25rem; }

/* ===== SKIP LINK ===== */
.skip-link {
  position: absolute;
  top: -100px;
  left: 0;
  background: var(--clr-primary);
  color: #fff;
  padding: 0.5rem 1rem;
  z-index: 9999;
  border-radius: 0 0 var(--radius) 0;
  transition: top 0.2s;
}
.skip-link:focus { top: 0; }

/* ===== STICKY HEADER ===== */
#site-header {
  position: fixed;
  top: 0; left: 0; right: 0;
  z-index: 1000;
  background: linear-gradient(135deg, var(--clr-primary) 0%, #1a3f6f 60%, #1e4a80 100%);
  color: #fff;
  height: var(--header-height);
  display: flex;
  align-items: center;
  gap: 0.875rem;
  padding: 0 1.25rem;
  box-shadow: 0 4px 24px rgba(15,45,82,0.25), 0 1px 0 rgba(255,255,255,0.08) inset;
  backdrop-filter: blur(12px);
  -webkit-backdrop-filter: blur(12px);
}
.header-logo {
  font-size: 1.5rem;
  flex-shrink: 0;
  filter: drop-shadow(0 2px 4px rgba(0,0,0,0.3));
  animation: pulse-logo 3s ease-in-out infinite;
}
@keyframes pulse-logo {
  0%, 100% { filter: drop-shadow(0 2px 4px rgba(0,0,0,0.3)); }
  50% { filter: drop-shadow(0 2px 12px rgba(255,100,100,0.5)); }
}
.header-title {
  font-size: 0.82rem;
  font-weight: 600;
  line-height: 1.3;
  flex: 1;
  overflow: hidden;
  display: -webkit-box;
  -webkit-line-clamp: 2;
  -webkit-box-orient: vertical;
  letter-spacing: -0.01em;
  opacity: 0.95;
}
/* ‚îÄ‚îÄ Header byline: compact attribution pill ‚îÄ‚îÄ */
.header-byline {
  display: flex;
  flex-direction: column;
  align-items: flex-end;
  justify-content: center;
  flex-shrink: 0;
  gap: 0.05rem;
  padding: 0.25rem 0.55rem;
  background: rgba(255,255,255,0.10);
  border: 1px solid rgba(255,255,255,0.18);
  border-radius: var(--radius-sm);
  line-height: 1.2;
  max-width: 130px;
}
.header-byline-brand {
  font-size: 0.68rem;
  font-weight: 800;
  color: #fff;
  letter-spacing: 0.01em;
  white-space: nowrap;
  text-shadow: 0 1px 3px rgba(0,0,0,0.3);
}
.header-byline-name {
  font-size: 0.58rem;
  font-weight: 500;
  color: rgba(255,255,255,0.72);
  white-space: nowrap;
  letter-spacing: 0.01em;
}
/* Hide name on very small screens, keep brand visible */
@media (max-width: 380px) {
  .header-byline-name { display: none; }
  .header-byline { padding: 0.2rem 0.4rem; }
}
/* Hide entire byline only on truly tiny screens if layout breaks */
@media (max-width: 300px) {
  .header-byline { display: none; }
}
#hamburger-btn {
  background: rgba(255,255,255,0.12);
  border: 1.5px solid rgba(255,255,255,0.2);
  border-radius: var(--radius-sm);
  color: #fff;
  padding: 0.4rem 0.6rem;
  font-size: 1.1rem;
  line-height: 1;
  min-width: 44px;
  min-height: 44px;
  display: flex;
  align-items: center;
  justify-content: center;
  flex-shrink: 0;
  transition: var(--transition);
}
#hamburger-btn:hover { background: rgba(255,255,255,0.22); transform: scale(1.05); }

/* ===== TOGGLE BAR ‚Äî Smart sliding ===== */
#toggle-bar {
  background: rgba(255,255,255,0.92);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border-bottom: 1px solid var(--clr-border-light);
  display: flex;
  gap: 0.5rem;
  padding: 0 1.25rem;
  flex-wrap: wrap;
  align-items: center;
  position: fixed;
  top: var(--header-height);
  left: 0;
  right: 0;
  z-index: 999;
  height: var(--togglebar-height);
  box-shadow: 0 2px 12px rgba(15,45,82,0.06);
  /* Slide transition */
  transform: translateY(0);
  transition: transform 0.3s cubic-bezier(0.4, 0, 0.2, 1);
}
#toggle-bar.hidden {
  transform: translateY(-100%);
}
/* Toggle bar reveal pill */
#toggle-bar-pill {
  position: fixed;
  top: calc(var(--header-height) + 2px);
  left: 50%;
  transform: translateX(-50%) translateY(0);
  z-index: 998;
  background: rgba(255,255,255,0.95);
  border: 1px solid var(--clr-border);
  border-top: none;
  border-radius: 0 0 20px 20px;
  padding: 2px 14px 4px;
  font-size: 0.65rem;
  color: var(--clr-text-subtle);
  cursor: pointer;
  box-shadow: 0 3px 8px rgba(15,45,82,0.12);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  display: flex;
  align-items: center;
  gap: 4px;
  font-weight: 600;
  letter-spacing: 0.04em;
  opacity: 0;
  pointer-events: none;
  font-family: var(--font-stack);
}
#toggle-bar-pill.visible {
  opacity: 1;
  pointer-events: all;
}
#toggle-bar-pill:hover {
  background: var(--clr-primary-light);
  color: var(--clr-primary);
  border-color: var(--clr-primary);
}
.toggle-label {
  font-size: 0.68rem;
  color: var(--clr-text-subtle);
  font-weight: 700;
  text-transform: uppercase;
  letter-spacing: 0.07em;
}
.toggle-btn {
  background: var(--clr-bg);
  border: 1.5px solid var(--clr-border);
  border-radius: var(--radius-xl);
  padding: 0.25rem 0.875rem;
  font-size: 0.73rem;
  font-weight: 600;
  color: var(--clr-text-muted);
  min-height: 32px;
  transition: var(--transition);
  letter-spacing: 0.01em;
  font-family: var(--font-stack);
  position: relative;
  overflow: hidden;
}
.toggle-btn::before {
  content: '';
  position: absolute;
  inset: 0;
  background: linear-gradient(135deg, var(--clr-primary), #1a3f6f);
  opacity: 0;
  transition: var(--transition);
}
.toggle-btn.active {
  border-color: transparent;
  color: #fff;
  box-shadow: 0 2px 8px rgba(15,45,82,0.25);
}
.toggle-btn.active::before { opacity: 1; }
.toggle-btn span { position: relative; z-index: 1; }
.toggle-btn:hover:not(.active) {
  border-color: var(--clr-primary);
  color: var(--clr-primary);
  background: var(--clr-primary-light);
}

/* Search highlight on matching cards */
.rec-card.search-highlight {
  outline: 2px solid var(--clr-accent2);
  outline-offset: 2px;
}

/* ===== LAYOUT ===== */
#layout {
  display: flex;
  min-height: 100vh;
  padding-top: var(--header-height);
}

/* ===== SIDEBAR / NAV ===== */
#sidebar {
  width: var(--sidebar-width);
  flex-shrink: 0;
  background: var(--clr-card);
  border-right: 1px solid var(--clr-border-light);
  position: fixed;
  top: var(--header-height);
  left: 0;
  bottom: 0;
  overflow-y: auto;
  z-index: 900;
  padding: 1.25rem 0 2rem;
  transform: translateX(-100%);
  transition: transform var(--transition-slow);
  scrollbar-width: thin;
  scrollbar-color: var(--clr-border) transparent;
}
#sidebar::-webkit-scrollbar { width: 4px; }
#sidebar::-webkit-scrollbar-thumb { background: var(--clr-border); border-radius: 4px; }
#sidebar.open { transform: translateX(0); box-shadow: var(--shadow-xl); }
#sidebar-backdrop {
  display: none;
  position: fixed;
  inset: 0;
  background: rgba(15,29,52,0.5);
  backdrop-filter: blur(4px);
  -webkit-backdrop-filter: blur(4px);
  z-index: 850;
}
#sidebar-backdrop.open { display: block; }
.toc-heading {
  font-size: 0.62rem;
  font-weight: 800;
  text-transform: uppercase;
  letter-spacing: 0.1em;
  color: var(--clr-text-subtle);
  padding: 1rem 1.25rem 0.35rem;
}
.toc-link {
  display: flex;
  align-items: center;
  padding: 0.38rem 1.25rem 0.38rem 1.5rem;
  font-size: 0.78rem;
  color: var(--clr-text-muted);
  border-left: 3px solid transparent;
  transition: var(--transition-fast);
  line-height: 1.35;
  position: relative;
}
.toc-link::before {
  content: '';
  position: absolute;
  left: 0; top: 0; bottom: 0;
  width: 3px;
  border-radius: 0 2px 2px 0;
  background: transparent;
  transition: var(--transition-fast);
}
.toc-link:hover {
  background: var(--clr-primary-light);
  color: var(--clr-primary);
  text-decoration: none;
}
.toc-link:hover::before { background: var(--clr-primary); opacity: 0.4; }
.toc-link.active {
  background: linear-gradient(90deg, var(--clr-primary-light), transparent);
  color: var(--clr-primary);
  font-weight: 600;
}
.toc-link.active::before { background: var(--clr-accent); opacity: 1; }
.toc-sub {
  font-size: 0.73rem;
  padding-left: 2rem;
}

/* ===== MAIN CONTENT ===== */
#main-content {
  flex: 1;
  min-width: 0;
  padding: 1.75rem 1.25rem 5rem;
}

/* ===== SECTIONS ===== */
.page-section {
  margin-bottom: 2.75rem;
  scroll-margin-top: calc(var(--header-height) + var(--togglebar-height) + 12px);
}
.section-title {
  font-size: 1.15rem;
  font-weight: 800;
  color: var(--clr-primary);
  margin-bottom: 1.25rem;
  padding-bottom: 0.625rem;
  border-bottom: 2px solid transparent;
  background: linear-gradient(var(--clr-card), var(--clr-card)) padding-box,
              linear-gradient(90deg, var(--clr-primary), var(--clr-steel), transparent) border-box;
  display: flex;
  align-items: center;
  gap: 0.625rem;
  letter-spacing: -0.02em;
}
.section-icon {
  font-size: 1.1rem;
  display: flex;
  align-items: center;
  justify-content: center;
  width: 36px;
  height: 36px;
  background: var(--clr-primary-light);
  border-radius: var(--radius-sm);
  flex-shrink: 0;
}

/* ===== HERO BOX ===== */
#hero {
  background: linear-gradient(135deg, var(--clr-primary) 0%, #1e4a80 40%, #2563b0 80%, #1d4ed8 100%);
  color: #fff;
  border-radius: var(--radius-lg);
  padding: 2rem;
  margin-bottom: 2.25rem;
  position: relative;
  overflow: hidden;
  box-shadow: var(--shadow-lg);
}
#hero::before {
  content: '';
  position: absolute;
  top: -60px; right: -60px;
  width: 240px; height: 240px;
  background: radial-gradient(circle, rgba(255,255,255,0.07) 0%, transparent 70%);
  pointer-events: none;
}
#hero::after {
  content: '';
  position: absolute;
  bottom: -40px; left: -40px;
  width: 180px; height: 180px;
  background: radial-gradient(circle, rgba(185,28,28,0.15) 0%, transparent 70%);
  pointer-events: none;
}
#hero h1 {
  font-size: 1.15rem;
  font-weight: 800;
  margin-bottom: 0.625rem;
  line-height: 1.3;
  letter-spacing: -0.02em;
  position: relative;
}
#hero .hero-meta {
  font-size: 0.8rem;
  opacity: 0.82;
  margin-bottom: 1rem;
  position: relative;
}
.hero-stats {
  display: flex;
  flex-wrap: wrap;
  gap: 0.75rem;
  margin-bottom: 1.25rem;
  position: relative;
}
.hero-stat {
  background: rgba(255,255,255,0.12);
  border: 1px solid rgba(255,255,255,0.15);
  border-radius: var(--radius);
  padding: 0.625rem 0.875rem;
  text-align: center;
  flex: 1;
  min-width: 80px;
  backdrop-filter: blur(8px);
  -webkit-backdrop-filter: blur(8px);
  transition: var(--transition);
}
.hero-stat:hover {
  background: rgba(255,255,255,0.18);
  transform: translateY(-2px);
}
.hero-stat .stat-number {
  font-size: 1.5rem;
  font-weight: 900;
  display: block;
  letter-spacing: -0.03em;
}
.hero-stat .stat-label {
  font-size: 0.63rem;
  opacity: 0.78;
  text-transform: uppercase;
  letter-spacing: 0.06em;
  font-weight: 600;
  margin-top: 0.1rem;
}
.key-takeaways {
  background: rgba(255,255,255,0.1);
  border: 1px solid rgba(255,255,255,0.15);
  border-radius: var(--radius);
  padding: 1.125rem;
  position: relative;
  backdrop-filter: blur(8px);
  -webkit-backdrop-filter: blur(8px);
}
.key-takeaways h3 {
  font-size: 0.78rem;
  font-weight: 800;
  margin-bottom: 0.625rem;
  text-transform: uppercase;
  letter-spacing: 0.07em;
  opacity: 0.9;
}
.key-takeaways ul {
  font-size: 0.82rem;
  list-style: none;
  padding: 0;
  display: grid;
  gap: 0.25rem;
}
.key-takeaways ul li {
  padding: 0.25rem 0 0.25rem 1.5rem;
  position: relative;
  line-height: 1.45;
  opacity: 0.92;
}
.key-takeaways ul li::before {
  content: '\2192';
  position: absolute;
  left: 0;
  color: rgba(255,200,100,0.9);
  font-weight: 700;
}

/* ===== CALLOUT BOXES ===== */
.callout {
  border-radius: var(--radius);
  padding: 0.875rem 1rem 0.875rem 1.125rem;
  margin: 0.875rem 0;
  font-size: 0.82rem;
  display: flex;
  gap: 0.75rem;
  align-items: flex-start;
  line-height: 1.5;
  border: 1px solid transparent;
  position: relative;
}
.callout-icon {
  flex-shrink: 0;
  font-size: 1.1rem;
  margin-top: 0.05rem;
  width: 24px;
  text-align: center;
}
.callout.danger {
  background: linear-gradient(135deg, #fff5f5, #fff0f0);
  border-color: #fca5a5;
  border-left: 4px solid var(--clr-accent);
  color: #7f1d1d;
}
.callout.warning {
  background: linear-gradient(135deg, #fffbeb, #fef9ec);
  border-color: #fcd34d;
  border-left: 4px solid var(--clr-accent2);
  color: #78350f;
}
.callout.success {
  background: linear-gradient(135deg, #f0fdf4, #ecfdf5);
  border-color: #86efac;
  border-left: 4px solid var(--clr-success);
  color: #14532d;
}
.callout.info {
  background: linear-gradient(135deg, #eff6ff, #eef2ff);
  border-color: #93c5fd;
  border-left: 4px solid var(--clr-steel);
  color: #1e3a8a;
}
.callout.purple {
  background: linear-gradient(135deg, #f5f3ff, #f0ebff);
  border-color: #c4b5fd;
  border-left: 4px solid var(--clr-purple);
  color: #4c1d95;
}

/* ===== GRADE DOTS ===== */
.grade-display {
  display: flex;
  align-items: center;
  gap: 3px;
  margin-left: 0.25rem;
}
.grade-dot {
  width: 12px;
  height: 12px;
  border-radius: 50%;
  display: inline-block;
  flex-shrink: 0;
  transition: transform var(--transition-fast);
}
.grade-dot:hover { transform: scale(1.2); }
.grade-dot.filled {
  background: radial-gradient(circle at 35% 35%, #34d399, var(--clr-success));
  box-shadow: 0 1px 4px rgba(21,128,61,0.4);
}
.grade-dot.empty {
  background: transparent;
  border: 1.5px solid #94a3b8;
}

/* ===== BADGES ===== */
.badge {
  display: inline-flex;
  align-items: center;
  gap: 0.2rem;
  font-size: 0.62rem;
  font-weight: 700;
  padding: 0.18rem 0.55rem;
  border-radius: var(--radius-xl);
  text-transform: uppercase;
  letter-spacing: 0.05em;
  white-space: nowrap;
  box-shadow: var(--shadow-xs);
}
.badge-strong {
  background: linear-gradient(135deg, #fef2f2, #fee2e2);
  color: #991b1b;
  border: 1px solid #fca5a5;
}
.badge-conditional {
  background: linear-gradient(135deg, #fffbeb, #fef3c7);
  color: #92400e;
  border: 1px solid #fcd34d;
}
.badge-certainty-vl {
  background: linear-gradient(135deg, #f8fafc, #f1f5f9);
  color: #475569;
  border: 1px solid #cbd5e1;
}
.badge-certainty-l {
  background: linear-gradient(135deg, #f0fdf4, #dcfce7);
  color: #166534;
  border: 1px solid #86efac;
}
.badge-certainty-m {
  background: linear-gradient(135deg, #eff6ff, #dbeafe);
  color: #1e40af;
  border: 1px solid #93c5fd;
}
.badge-certainty-h {
  background: linear-gradient(135deg, #f0fdf4, #bbf7d0);
  color: #14532d;
  border: 1px solid #4ade80;
}

/* ===== RECOMMENDATION CARDS ===== */
.rec-card {
  background: var(--clr-card);
  border-radius: var(--radius-lg);
  box-shadow: var(--shadow-sm);
  margin-bottom: 1.125rem;
  border-left: 5px solid var(--clr-primary);
  overflow: hidden;
  transition: box-shadow var(--transition), transform var(--transition);
  position: relative;
  /* Fallback for browsers that don't honour scroll-padding-top on html */
  scroll-margin-top: calc(var(--header-height) + var(--togglebar-height) + 12px);
}
.rec-card::after {
  content: '';
  position: absolute;
  inset: 0;
  border-radius: inherit;
  border: 1px solid rgba(255,255,255,0.8);
  pointer-events: none;
}
.rec-card:hover {
  box-shadow: var(--shadow-md);
  transform: translateY(-1px);
}
.rec-card.open {
  box-shadow: var(--shadow-md);
}

/* Category colours */
.rec-card.cat-dvt-pe { border-left-color: var(--clr-primary); }
.rec-card.cat-csvt { border-left-color: var(--clr-purple); }
.rec-card.cat-rat { border-left-color: var(--clr-accent2); }
.rec-card.cat-rvt { border-left-color: var(--clr-teal); }
.rec-card.cat-pvt { border-left-color: var(--clr-brown); }
.rec-card.cat-svt { border-left-color: #64748b; }
.rec-card.cat-pe-thrombolysis { border-left-color: var(--clr-crimson); }
.rec-card.cat-cvad { border-left-color: var(--clr-steel); }
.rec-card.cat-doac { border-left-color: var(--clr-success); }

.rec-card-header {
  padding: 1rem 1.125rem 0.875rem;
  background: var(--clr-card);
  border-bottom: 1px solid var(--clr-border-light);
  cursor: pointer;
  display: flex;
  align-items: flex-start;
  gap: 0.625rem;
  transition: background var(--transition-fast);
  user-select: none;
}
.rec-card-header:hover { background: #fafbff; }
.rec-card.open .rec-card-header { background: var(--clr-primary-light); border-bottom-color: var(--clr-border); }

.rec-number {
  background: var(--clr-primary);
  color: #fff;
  font-size: 0.68rem;
  font-weight: 800;
  padding: 0.22rem 0.55rem;
  border-radius: var(--radius-sm);
  flex-shrink: 0;
  white-space: nowrap;
  letter-spacing: 0.03em;
  box-shadow: var(--shadow-xs);
}
.rec-card.cat-csvt .rec-number { background: var(--clr-purple); }
.rec-card.cat-rat .rec-number { background: var(--clr-accent2); }
.rec-card.cat-rvt .rec-number { background: var(--clr-teal); }
.rec-card.cat-pvt .rec-number { background: var(--clr-brown); }
.rec-card.cat-svt .rec-number { background: #64748b; }
.rec-card.cat-pe-thrombolysis .rec-number { background: var(--clr-crimson); }
.rec-card.cat-cvad .rec-number { background: var(--clr-steel); }
.rec-card.cat-doac .rec-number { background: var(--clr-success); }

.rec-title-block { flex: 1; min-width: 0; }
.rec-short-title {
  font-size: 0.88rem;
  font-weight: 700;
  color: var(--clr-primary);
  line-height: 1.25;
  margin-bottom: 0.35rem;
  letter-spacing: -0.01em;
}
.rec-badges { display: flex; gap: 0.3rem; flex-wrap: wrap; align-items: center; }
.rec-chevron {
  font-size: 0.8rem;
  color: #94a3b8;
  transition: transform var(--transition);
  flex-shrink: 0;
  margin-top: 0.2rem;
  width: 20px;
  height: 20px;
  display: flex;
  align-items: center;
  justify-content: center;
  background: var(--clr-bg);
  border-radius: 50%;
}
.rec-card.open .rec-chevron {
  transform: rotate(180deg);
  background: var(--clr-primary-light);
  color: var(--clr-primary);
}

.rec-card-body { display: none; padding: 0; }
.rec-card.open .rec-card-body { display: block; }

.rec-statement {
  background: linear-gradient(135deg, #f8f9ff, #eef2ff);
  border-left: 4px solid var(--clr-steel);
  margin: 0.875rem 1.125rem;
  padding: 0.875rem 1rem;
  border-radius: 0 var(--radius) var(--radius) 0;
  font-size: 0.84rem;
  font-style: italic;
  line-height: 1.55;
  color: var(--clr-text);
  position: relative;
}
.rec-statement::before {
  content: '\201C';
  position: absolute;
  top: -0.5rem;
  left: 0.75rem;
  font-size: 3rem;
  color: var(--clr-steel);
  opacity: 0.15;
  font-style: normal;
  line-height: 1;
  font-family: Georgia, serif;
}
.rec-statement strong { font-style: normal; color: var(--clr-primary); }

/* ===== CARD PANELS ===== */
.card-panels { padding: 0 1.125rem 1.125rem; }
.panel-tabs {
  display: flex;
  gap: 0.25rem;
  flex-wrap: wrap;
  margin-bottom: 0.875rem;
  background: var(--clr-bg);
  border-radius: var(--radius-sm);
  padding: 0.25rem;
}
.panel-tab {
  background: transparent;
  border: none;
  border-radius: var(--radius-sm);
  padding: 0.3rem 0.75rem;
  font-size: 0.72rem;
  font-weight: 600;
  color: var(--clr-text-muted);
  cursor: pointer;
  transition: var(--transition-fast);
  font-family: var(--font-stack);
  letter-spacing: 0.01em;
}
.panel-tab.active {
  background: var(--clr-card);
  color: var(--clr-primary);
  box-shadow: var(--shadow-xs);
}
.panel-tab:hover:not(.active) {
  color: var(--clr-primary);
  background: rgba(255,255,255,0.6);
}
.panel-content { display: none; }
.panel-content.active { display: block; }
.panel-heading {
  font-size: 0.73rem;
  font-weight: 800;
  color: var(--clr-primary);
  text-transform: uppercase;
  letter-spacing: 0.07em;
  margin-bottom: 0.625rem;
  display: flex;
  align-items: center;
  gap: 0.375rem;
}
.panel-heading::before {
  content: '';
  display: block;
  width: 3px;
  height: 14px;
  background: var(--clr-primary);
  border-radius: 2px;
}
.panel-content ul, .panel-content ol {
  font-size: 0.82rem;
  line-height: 1.6;
}
.panel-content p { font-size: 0.82rem; line-height: 1.6; margin-bottom: 0.5rem; }
.panel-content li { margin-bottom: 0.3rem; }

/* evidence and implementation panels ‚Äî hidden by default, show with toggles */
.evidence-panel { display: none; }
#main-content.show-evidence .evidence-panel::before {
  content: 'üìä Evidence Summary';
  display: block;
  font-size: 0.65rem;
  font-weight: 800;
  text-transform: uppercase;
  letter-spacing: 0.08em;
  color: var(--clr-primary);
  border-bottom: 1px solid var(--clr-border-light);
  padding-bottom: 0.375rem;
  margin-bottom: 0.5rem;
  opacity: 0.7;
}
#main-content.show-implementation .impl-panel::before {
  content: '‚öôÔ∏è Implementation';
  display: block;
  font-size: 0.65rem;
  font-weight: 800;
  text-transform: uppercase;
  letter-spacing: 0.08em;
  color: var(--clr-success);
  border-bottom: 1px solid var(--clr-border-light);
  padding-bottom: 0.375rem;
  margin-bottom: 0.5rem;
  opacity: 0.7;
}
.impl-panel { display: none; }
.quick-content { display: none; }

/* Toggle state classes on main */

/* === EVIDENCE MODE === */
/* Show the card body and the evidence panel */
#main-content.show-evidence .rec-card-body { display: block; }
#main-content.show-evidence .evidence-panel { display: block; }
/* Hide the tabbed panel area so only evidence shows cleanly */
#main-content.show-evidence .panel-tabs { opacity: 0.4; pointer-events: none; }

/* === IMPLEMENTATION MODE === */
#main-content.show-implementation .rec-card-body { display: block; }
#main-content.show-implementation .impl-panel { display: block; }
#main-content.show-implementation .panel-tabs { opacity: 0.4; pointer-events: none; }

/* === QUICK VIEW MODE === */
#main-content.quick-view .rec-card-body { display: block; }
#main-content.quick-view .evidence-panel { display: none !important; }
#main-content.quick-view .impl-panel { display: none !important; }
#main-content.quick-view .quick-content { display: block !important; }
#main-content.quick-view .panel-tabs { display: none; }
#main-content.quick-view .panel-content { display: none; }

/* Restore panel-tabs opacity when no view mode active */
#main-content:not(.show-evidence):not(.show-implementation) .panel-tabs { opacity: 1; pointer-events: all; }

/* ===== GPS CARDS ===== */
.gps-card {
  background: linear-gradient(135deg, #f0fdfa, #ccfbf1);
  border-radius: var(--radius);
  box-shadow: var(--shadow-sm);
  border: 1px solid #99f6e4;
  border-left: 5px solid var(--clr-teal);
  padding: 1.125rem;
  margin-bottom: 0.875rem;
  transition: var(--transition);
}
.gps-card:hover { box-shadow: var(--shadow-md); transform: translateY(-1px); }
.gps-label {
  font-size: 0.65rem;
  font-weight: 800;
  text-transform: uppercase;
  letter-spacing: 0.09em;
  color: var(--clr-teal);
  margin-bottom: 0.5rem;
  display: flex;
  align-items: center;
  gap: 0.375rem;
}
.gps-label::before {
  content: '\2713';
  display: flex;
  align-items: center;
  justify-content: center;
  width: 18px;
  height: 18px;
  background: var(--clr-teal);
  color: #fff;
  border-radius: 50%;
  font-size: 0.65rem;
  font-weight: 900;
}
.gps-text { font-size: 0.85rem; line-height: 1.6; color: var(--clr-text); }

/* ===== AGE DEFINITIONS TABLE ===== */
.age-table {
  width: 100%;
  border-collapse: separate;
  border-spacing: 0;
  font-size: 0.82rem;
  margin: 0.875rem 0;
  border-radius: var(--radius);
  overflow: hidden;
  box-shadow: var(--shadow-sm);
  border: 1px solid var(--clr-border);
}
.age-table th {
  background: linear-gradient(135deg, var(--clr-primary), #1a3f6f);
  color: #fff;
  padding: 0.625rem 0.75rem;
  text-align: left;
  font-size: 0.73rem;
  font-weight: 700;
  letter-spacing: 0.04em;
}
.age-table td {
  padding: 0.5rem 0.75rem;
  border-bottom: 1px solid var(--clr-border-light);
  vertical-align: top;
}
.age-table tr:nth-child(even) td { background: #fafbfd; }
.age-table tr:last-child td { border-bottom: none; }
.age-table tr:hover td { background: var(--clr-primary-light); }

/* ===== TABLE 2 (2018 recs not addressed) ===== */
.table2-group {
  background: var(--clr-card);
  border-radius: var(--radius);
  box-shadow: var(--shadow-sm);
  margin-bottom: 1rem;
  overflow: hidden;
  border: 1px solid var(--clr-border-light);
  transition: var(--transition);
}
.table2-group:hover { box-shadow: var(--shadow-md); }
.table2-group-header {
  background: linear-gradient(135deg, var(--clr-primary), #1a3f6f);
  color: #fff;
  padding: 0.75rem 1.125rem;
  font-size: 0.82rem;
  font-weight: 700;
  letter-spacing: -0.01em;
}
.table2-item {
  padding: 0.875rem 1.125rem;
  border-bottom: 1px solid var(--clr-border-light);
  font-size: 0.82rem;
  transition: background var(--transition-fast);
}
.table2-item:hover { background: var(--clr-bg); }
.table2-item:last-child { border-bottom: none; }
.table2-rec-num {
  font-weight: 700;
  color: var(--clr-primary);
  font-size: 0.75rem;
  margin-bottom: 0.25rem;
  letter-spacing: -0.01em;
}
.table2-item p { color: var(--clr-text-muted); line-height: 1.5; margin-top: 0.25rem; }
.table2-item .remarks {
  font-size: 0.76rem;
  color: var(--clr-text-subtle);
  margin-top: 0.4rem;
  font-style: italic;
  padding-left: 0.75rem;
  border-left: 2px solid var(--clr-border);
}

/* ===== DRUG IMPLEMENTATION SECTION ===== */
.drug-card {
  background: var(--clr-card);
  border-radius: var(--radius);
  box-shadow: var(--shadow-sm);
  padding: 1.125rem;
  margin-bottom: 1rem;
  border-left: 5px solid var(--clr-success);
  transition: var(--transition);
  border: 1px solid var(--clr-border-light);
  border-left-width: 5px;
}
.drug-card:hover { box-shadow: var(--shadow-md); transform: translateY(-1px); }
.drug-card h3 {
  font-size: 0.9rem;
  font-weight: 700;
  color: var(--clr-primary);
  margin-bottom: 0.625rem;
  letter-spacing: -0.01em;
}
.drug-card ul { font-size: 0.82rem; line-height: 1.6; }

/* ===== SPECIAL SITUATIONS ===== */
.situation-card {
  background: var(--clr-card);
  border-radius: var(--radius);
  box-shadow: var(--shadow-sm);
  margin-bottom: 0.875rem;
  overflow: hidden;
  border: 1px solid var(--clr-border-light);
  transition: box-shadow var(--transition);
}
.situation-card:hover { box-shadow: var(--shadow-md); }
.situation-header {
  background: linear-gradient(90deg, var(--clr-primary) 0%, #1a3f6f 60%, #1e4a80 100%);
  color: #fff;
  padding: 0.875rem 1.125rem;
  font-size: 0.875rem;
  font-weight: 700;
  cursor: pointer;
  display: flex;
  justify-content: space-between;
  align-items: center;
  user-select: none;
  letter-spacing: -0.01em;
}
.situation-header:hover { background: linear-gradient(90deg, #1a3f6f 0%, #1e4a80 100%); }
.situation-body {
  padding: 1.125rem;
  display: none;
  font-size: 0.82rem;
  line-height: 1.6;
  border-top: 1px solid var(--clr-border-light);
}
.situation-card.open .situation-body { display: block; }
.situation-card.open .situation-chevron { transform: rotate(180deg); }
.situation-chevron { transition: transform var(--transition); }

/* ===== EVIDENCE / TRIAL CARDS ===== */
.trial-card {
  background: var(--clr-card);
  border-radius: var(--radius);
  box-shadow: var(--shadow-sm);
  padding: 1.125rem;
  margin-bottom: 0.875rem;
  border-top: 4px solid var(--clr-primary);
  border: 1px solid var(--clr-border-light);
  border-top-width: 4px;
  transition: var(--transition);
  position: relative;
  overflow: hidden;
}
.trial-card::before {
  content: '';
  position: absolute;
  top: 0; right: 0;
  width: 80px; height: 80px;
  background: radial-gradient(circle, var(--clr-primary-light), transparent);
  border-radius: 0 var(--radius) 0 100%;
}
.trial-card:hover { box-shadow: var(--shadow-md); transform: translateY(-1px); }
.trial-name {
  font-weight: 800;
  color: var(--clr-primary);
  font-size: 1rem;
  margin-bottom: 0.3rem;
  letter-spacing: -0.02em;
  position: relative;
}
.trial-meta {
  font-size: 0.73rem;
  color: var(--clr-text-subtle);
  margin-bottom: 0.625rem;
  padding: 0.25rem 0.625rem;
  background: var(--clr-bg);
  border-radius: var(--radius-sm);
  display: inline-block;
}
.trial-card p { font-size: 0.82rem; line-height: 1.6; }

/* ===== BACK TO TOP FAB ===== */
#back-to-top {
  position: fixed;
  bottom: 1.75rem;
  right: 1.75rem;
  background: linear-gradient(135deg, var(--clr-primary), #1a3f6f);
  color: #fff;
  width: 52px;
  height: 52px;
  border-radius: 50%;
  font-size: 1.1rem;
  display: flex;
  align-items: center;
  justify-content: center;
  box-shadow: 0 4px 20px rgba(15,45,82,0.35), 0 2px 8px rgba(15,45,82,0.2);
  z-index: 800;
  opacity: 0;
  pointer-events: none;
  transition: opacity var(--transition), transform var(--transition);
  border: none;
  letter-spacing: 0;
}
#back-to-top.visible {
  opacity: 1;
  pointer-events: auto;
}
#back-to-top:hover { transform: translateY(-3px) scale(1.05); }

/* ===== DISCLAIMER ===== */
#disclaimer {
  background: linear-gradient(135deg, #fffbeb, #fef9e8);
  border: 1px solid #fcd34d;
  border-left: 5px solid var(--clr-accent2);
  border-radius: var(--radius);
  padding: 1.25rem;
  font-size: 0.8rem;
  color: #78350f;
  line-height: 1.65;
  box-shadow: var(--shadow-sm);
}
#disclaimer .disclaimer-icon {
  font-size: 1.5rem;
  display: block;
  margin-bottom: 0.625rem;
}

/* ===== CHECKLIST ===== */
.checklist { list-style: none; padding: 0; }
.checklist li {
  padding: 0.3rem 0 0.3rem 2rem;
  position: relative;
  font-size: 0.82rem;
  line-height: 1.5;
  transition: color var(--transition-fast);
}
.checklist li::before {
  content: '';
  position: absolute;
  left: 0;
  top: 0.35rem;
  width: 18px;
  height: 18px;
  border: 2px solid var(--clr-border);
  border-radius: 4px;
  background: white;
}
.checklist li.check::before {
  content: '\2713';
  border-color: var(--clr-success);
  background: var(--clr-success-light);
  color: var(--clr-success);
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: 900;
  font-size: 0.7rem;
}
.checklist li.cross::before {
  content: '\2717';
  border-color: var(--clr-accent);
  background: var(--clr-accent-light);
  color: var(--clr-accent);
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: 900;
  font-size: 0.7rem;
}

/* ===== OVERVIEW GRID ===== */
.overview-grid {
  display: grid;
  gap: 0.875rem;
  grid-template-columns: 1fr;
}

/* ===== COLOUR LEGEND ===== */
.legend {
  display: flex;
  flex-wrap: wrap;
  gap: 0.5rem;
  margin: 0.875rem 0;
}
.legend-item {
  display: flex;
  align-items: center;
  gap: 0.4rem;
  font-size: 0.73rem;
  color: var(--clr-text-muted);
  background: var(--clr-card);
  border: 1px solid var(--clr-border-light);
  border-radius: var(--radius-xl);
  padding: 0.2rem 0.625rem 0.2rem 0.4rem;
  box-shadow: var(--shadow-xs);
}
.legend-dot {
  width: 10px;
  height: 10px;
  border-radius: 50%;
  flex-shrink: 0;
  box-shadow: 0 1px 3px rgba(0,0,0,0.15);
}

/* ===== HIGHLIGHTS ===== */
mark {
  background: linear-gradient(120deg, #fef08a, #fde047);
  padding: 0 3px;
  border-radius: 3px;
  font-weight: 600;
}

/* ===== STRONG RECOMMENDATION HIGHLIGHT ===== */
.strong-rec-highlight {
  background: linear-gradient(135deg, #fff5f5, #ffe8e8);
  border: 2px solid #fca5a5;
  box-shadow: 0 0 0 4px rgba(185,28,28,0.06);
}

/* ===== PICO QUESTION ===== */
.pico-q {
  background: linear-gradient(135deg, #eef2ff, #e8f0fb);
  border-radius: var(--radius-sm);
  padding: 0.5rem 0.875rem;
  font-size: 0.77rem;
  color: #1e3a8a;
  margin-bottom: 0.625rem;
  font-style: italic;
  border: 1px solid #bfdbfe;
  border-left: 3px solid var(--clr-steel);
}
.pico-label {
  font-style: normal;
  font-weight: 800;
  color: var(--clr-steel);
  font-size: 0.62rem;
  display: block;
  text-transform: uppercase;
  letter-spacing: 0.07em;
  margin-bottom: 0.2rem;
}

/* ===== DATA TABLE ===== */
.data-table {
  width: 100%;
  border-collapse: separate;
  border-spacing: 0;
  font-size: 0.78rem;
  margin: 0.625rem 0;
  border-radius: var(--radius-sm);
  overflow: hidden;
  border: 1px solid var(--clr-border);
}
.data-table th {
  background: linear-gradient(135deg, var(--clr-primary), #1a3f6f);
  color: #fff;
  padding: 0.45rem 0.625rem;
  text-align: left;
  font-weight: 700;
  letter-spacing: 0.03em;
}
.data-table td {
  padding: 0.375rem 0.625rem;
  border-bottom: 1px solid var(--clr-border-light);
  vertical-align: top;
}
.data-table tr:nth-child(even) td { background: #fafbfd; }
.data-table tr:hover td { background: var(--clr-primary-light); }

/* ===== TABLET / DESKTOP ===== */
@media (min-width: 768px) {
  .header-title { font-size: 0.9rem; -webkit-line-clamp: 1; }
  #hamburger-btn { display: none; }
  #sidebar { transform: translateX(0); position: fixed; }
  #sidebar-backdrop { display: none !important; }
  #layout { padding-left: var(--sidebar-width); }
  #main-content { padding: 2rem 1.75rem 5rem; }
  .overview-grid { grid-template-columns: 1fr 1fr; }
  .hero-stats { flex-wrap: nowrap; }
  #hero h1 { font-size: 1.3rem; }
  .rec-cards-grid {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 1rem;
  }
  .rec-cards-grid .rec-card { margin-bottom: 0; }
  .rec-cards-grid .rec-card.full-width { grid-column: 1 / -1; }
}

@media (min-width: 1200px) {
  #main-content { padding: 2.25rem 3rem 5rem; max-width: 980px; }
}

/* ===== PRINT ===== */
@media print {
  #site-header, #toggle-bar, #sidebar, #back-to-top, #hamburger-btn { display: none !important; }
  #layout { padding: 0; }
  #main-content { padding: 0; max-width: 100%; }
  .rec-card-body { display: block !important; }
  .panel-content { display: block !important; }
  .evidence-panel, .impl-panel { display: block !important; }
  .rec-card {
    break-inside: avoid;
    box-shadow: none;
    border: 1px solid #ccc;
    border-left: 5px solid #333;
    margin-bottom: 1rem;
    border-radius: 0;
    transform: none !important;
  }
  body { font-size: 10.5pt; background: white; }
  .section-title { font-size: 13pt; border-bottom: 1pt solid #333; }
  .trial-card { box-shadow: none; border: 1pt solid #ccc; border-radius: 0; }
  #hero { background: #0f2d52 !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; border-radius: 0; }
}
</style>
<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

<!-- STICKY HEADER -->
<header id="site-header" role="banner">
  <div class="header-logo" aria-hidden="true">ü©∏</div>
  <div class="header-title">ASH/ISTH 2024 ‚Äî VTE in Paediatric Patients Guidelines</div>
  <div class="header-byline" aria-label="Created by Bloodü©∏Doctor">
    <span class="header-byline-brand">Bloodü©∏Doctor</span>
    <span class="header-byline-name">Dr Abdul Mannan</span>
  </div>
  <button id="theme-toggle-btn" aria-label="Toggle dark mode" title="Toggle dark/light mode" style="background:rgba(255,255,255,0.12);border:1.5px solid rgba(255,255,255,0.2);border-radius:var(--radius-sm);color:#fff;padding:0.4rem 0.6rem;font-size:1rem;line-height:1;min-width:40px;min-height:40px;display:flex;align-items:center;justify-content:center;flex-shrink:0;transition:var(--transition);cursor:pointer;font-family:inherit;">&#x1F319;</button>
      <button id="hamburger-btn" aria-label="Open table of contents" aria-expanded="false" aria-controls="sidebar">‚ò∞</button>
</header>

<!-- TOGGLE BAR -->
<div id="toggle-bar" role="toolbar" aria-label="View controls">
  <span class="toggle-label">View mode:</span>
  <button class="toggle-btn" id="btn-evidence" aria-pressed="false"><span>&#128202; Evidence</span></button>
  <button class="toggle-btn" id="btn-implementation" aria-pressed="false"><span>&#9881; Implementation</span></button>
  <button class="toggle-btn" id="btn-quickview" aria-pressed="false"><span>&#9889; Quick View</span></button>
</div>

<!-- SIDEBAR BACKDROP -->
<button id="toggle-bar-pill" aria-label="Show view controls">&#9660; View</button>
<div id="sidebar-backdrop" aria-hidden="true"></div>

<!-- MAIN LAYOUT -->
<div id="layout">

  <!-- SIDEBAR / TOC -->
  <nav id="sidebar" role="navigation" aria-label="Table of contents">
    <div class="toc-heading">Contents</div>
    <a class="toc-link" href="#hero">Key Takeaways</a>
    <a class="toc-link" href="#overview">Overview &amp; Methods</a>
    <a class="toc-link" href="#age-definitions">Age Definitions</a>
    <a class="toc-link" href="#good-practice">Good Practice Statements</a>

    <div class="toc-heading">Recommendations</div>
    <a class="toc-link toc-sub" href="#rec1">1 ‚Äî Symptomatic DVT/PE</a>
    <a class="toc-link toc-sub" href="#rec2">2 ‚Äî Unsuspected DVT/PE</a>
    <a class="toc-link toc-sub" href="#rec3">3 ‚Äî Provoked VTE Duration</a>
    <a class="toc-link toc-sub" href="#rec4">4 ‚Äî Unprovoked VTE Duration</a>
    <a class="toc-link toc-sub" href="#rec5">5 ‚Äî CSVT Treatment</a>
    <a class="toc-link toc-sub" href="#rec6">6 ‚Äî CSVT Thrombolysis</a>
    <a class="toc-link toc-sub" href="#rec7">7a/b ‚Äî RAT</a>
    <a class="toc-link toc-sub" href="#rec8">8 ‚Äî RAT Thrombolysis</a>
    <a class="toc-link toc-sub" href="#rec9">9 ‚Äî RVT Neonatal</a>
    <a class="toc-link toc-sub" href="#rec10">10a/b ‚Äî RVT Thrombolysis</a>
    <a class="toc-link toc-sub" href="#rec11">11a/b ‚Äî PVT</a>
    <a class="toc-link toc-sub" href="#rec12">12a/b ‚Äî SVT</a>
    <a class="toc-link toc-sub" href="#rec13">13 ‚Äî Proximal DVT Thrombolysis</a>
    <a class="toc-link toc-sub" href="#rec14">14 ‚Äî Submassive PE</a>
    <a class="toc-link toc-sub" href="#rec15">15 ‚Äî Massive PE</a>
    <a class="toc-link toc-sub" href="#rec16">16 ‚Äî CVAD Removal</a>
    <a class="toc-link toc-sub" href="#rec17">17 ‚Äî DOACs vs SOC</a>
    <a class="toc-link toc-sub" href="#rec18">18 ‚Äî Rivaroxaban</a>
    <a class="toc-link toc-sub" href="#rec19">19 ‚Äî Dabigatran</a>
    <a class="toc-link toc-sub" href="#rec20">20 ‚Äî Rivaroxaban vs Dabigatran</a>

    <div class="toc-heading">Other Sections</div>
    <a class="toc-link" href="#drug-implementation">Drug Implementation</a>
    <a class="toc-link" href="#special-situations">Special Situations</a>
    <a class="toc-link" href="#table2">2018 Recs Not Updated</a>
    <a class="toc-link" href="#evidence">Evidence &amp; Key Trials</a>
    <a class="toc-link" href="#disclaimer">Disclaimer</a>
  </nav>

  <!-- MAIN CONTENT -->
  <main id="main-content" tabindex="-1">

    <!-- HERO -->
    <section id="hero" class="page-section">
      <h1>ASH/ISTH 2024 Updated Guidelines for Treatment of Venous Thromboembolism in Paediatric Patients</h1>
      <p class="hero-meta">Blood Advances ¬∑ 27 May 2025 ¬∑ Vol 9, No 10, pp 2587‚Äì2606 ¬∑ DOI: <a href="https://doi.org/10.1182/bloodadvances.2024015328" style="color:#90cdf4;" target="_blank" rel="noopener">10.1182/bloodadvances.2024015328</a></p>
      <p class="hero-meta" style="margin-bottom:0.75rem;">Paul Monagle et al (30 co-authors) ¬∑ GRADE Methodology</p>
      <div class="hero-stats">
        <div class="hero-stat"><span class="stat-number">20</span><span class="stat-label">Recommendations</span></div>
        <div class="hero-stat"><span class="stat-number">2</span><span class="stat-label">Good Practice Stmts</span></div>
        <div class="hero-stat"><span class="stat-number">1</span><span class="stat-label">Strong Rec (Rec 10a)</span></div>
        <div class="hero-stat"><span class="stat-number">‚äï‚óã‚óã‚óã</span><span class="stat-label">Mostly Very Low Certainty</span></div>
      </div>
      <div class="key-takeaways">
        <h3>Key Takeaways</h3>
        <ul>
          <li>All recommendations are <strong>conditional</strong> except Rec 10a (strong recommendation AGAINST thrombolysis in non-life-threatening neonatal RVT)</li>
          <li>Nearly all are based on <strong>very low certainty evidence</strong> (‚äï‚óã‚óã‚óã); Rec 16 is LOW certainty (‚äï‚äï‚óã‚óã)</li>
          <li>DOACs (rivaroxaban/dabigatran) now <strong>preferred over SOC</strong> (LMWH/UFH/VKA) in most paediatric patients ‚Äî Recs 17‚Äì20</li>
          <li>Kids-DOTT trial supports <strong>6 weeks over 3 months</strong> for select provoked VTE (strict criteria apply) ‚Äî Rec 3</li>
          <li>CSVT recommendation <strong>downgraded from Strong (2018) to Conditional (2024)</strong> ‚Äî Rec 5</li>
          <li>Anticoagulation in symptomatic CVAD-related VTE: specific exceptions for neonates and trauma ‚Äî Rec 1</li>
          <li>Apixaban and edoxaban: <strong>NOT included</strong> ‚Äî phase 3 paediatric trial data not yet published</li>
          <li>A paediatric haematologist or haematology-trained paediatrician should implement these guidelines (GPS 1)</li>
        </ul>
      </div>
    </section>

    <!-- OVERVIEW -->
    <section id="overview" class="page-section">
      <h2 class="section-title"><span class="section-icon">üìã</span> Overview &amp; Methods</h2>
      <div class="overview-grid">
        <div class="drug-card" style="border-left-color: var(--clr-primary);">
          <h3>Publication Details</h3>
          <ul>
            <li><strong>Full title:</strong> American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients</li>
            <li><strong>Journal:</strong> Blood Advances, Vol 9, No 10, pp 2587‚Äì2606+</li>
            <li><strong>Published:</strong> 27 May 2025</li>
            <li><strong>DOI:</strong> 10.1182/bloodadvances.2024015328</li>
            <li><strong>Lead author:</strong> Paul Monagle et al (30 co-authors)</li>
            <li><strong>Total recommendations:</strong> 20 plus 2 Good Practice Statements</li>
          </ul>
        </div>
        <div class="drug-card" style="border-left-color: var(--clr-purple);">
          <h3>Methodology</h3>
          <ul>
            <li><strong>Framework:</strong> GRADE methodology</li>
            <li><strong>All recommendations:</strong> Conditional unless stated</li>
            <li><strong>Certainty:</strong> Predominantly very low (‚äï‚óã‚óã‚óã); Rec 16 = low (‚äï‚äï‚óã‚óã)</li>
            <li><strong>Strong recommendation:</strong> Rec 10a only</li>
            <li><strong>Scope:</strong> Update to 2018 ASH guidelines; addresses 20 new/updated PICO questions</li>
            <li><strong>Update trigger:</strong> Publication of EINSTEIN-Junior, DIVERSITY, and Kids-DOTT RCTs</li>
          </ul>
        </div>
      </div>

      <div class="callout info">
        <span class="callout-icon">‚Ñπ</span>
        <div><strong>GRADE Certainty Summary:</strong>
          <span style="margin-left:0.5rem;">‚äï‚äï‚äï‚äï High</span>
          <span style="margin-left:0.5rem;">‚äï‚äï‚äï‚óã Moderate</span>
          <span style="margin-left:0.5rem;">‚äï‚äï‚óã‚óã Low</span>
          <span style="margin-left:0.5rem;">‚äï‚óã‚óã‚óã Very Low</span>
          ‚Äî Most recommendations in this guideline are ‚äï‚óã‚óã‚óã (Very Low)
        </div>
      </div>

      <h3 style="font-size:0.9rem; margin:1rem 0 0.5rem; color:var(--clr-primary);">Category Colour Key</h3>
      <div class="legend">
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-primary);"></div> DVT/PE</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-purple);"></div> CSVT</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-accent2);"></div> RAT</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-teal);"></div> RVT</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-brown);"></div> PVT</div>
        <div class="legend-item"><div class="legend-dot" style="background:#7f8c8d;"></div> SVT</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-crimson);"></div> PE Thrombolysis</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-steel);"></div> CVAD</div>
        <div class="legend-item"><div class="legend-dot" style="background:var(--clr-success);"></div> DOACs/Drugs</div>
      </div>
    </section>

    <!-- AGE DEFINITIONS -->
    <section id="age-definitions" class="page-section">
      <h2 class="section-title"><span class="section-icon">üë∂</span> Age Definitions (Panel Terminology)</h2>
      <table class="age-table">
        <thead>
          <tr><th>Term</th><th>Age Range</th><th>Notes</th></tr>
        </thead>
        <tbody>
          <tr><td><strong>Neonates</strong></td><td>Birth to day 28</td><td>Highest bleeding risk; specific considerations apply</td></tr>
          <tr><td><strong>Infants</strong></td><td>Day 29 to 1 year</td><td>Distinct pharmacokinetics; weight-based dosing critical</td></tr>
          <tr><td><strong>Children</strong></td><td>Age 1‚Äì11 years</td><td>Most paediatric dosing studies include this group</td></tr>
          <tr><td><strong>Adolescents</strong></td><td>Age 12‚Äì18 years</td><td>Closer to adult pharmacokinetics; menstrual bleeding relevant (rivaroxaban)</td></tr>
          <tr><td><strong>Paediatric patients</strong></td><td>All age groups combined</td><td>Used when all ages are included in the recommendation</td></tr>
          <tr><td><strong>Neonates AND paediatric patients</strong></td><td>Neonates separated from all others</td><td>Used when neonatal data are specifically distinguished</td></tr>
        </tbody>
      </table>
      <div class="callout warning">
        <span class="callout-icon">‚ö†</span>
        <div>Dosing and pharmacokinetics vary substantially across age groups. Recommendations cannot be assumed to apply uniformly across the entire age spectrum ‚Äî neonates in particular require individual assessment.</div>
      </div>
    </section>

    <!-- GOOD PRACTICE STATEMENTS -->
    <section id="good-practice" class="page-section">
      <h2 class="section-title"><span class="section-icon">‚úÖ</span> Good Practice Statements</h2>
      <p style="font-size:0.82rem; color:#555; margin-bottom:1rem;">Good Practice Statements (GPS) are not derived from formal evidence review but reflect actions that, in the panel's view, are self-evidently beneficial given the complexity of care.</p>

      <div class="gps-card">
        <div class="gps-label">Good Practice Statement 1 ‚Äî Specialist Involvement</div>
        <p class="gps-text">A paediatric haematologist or a paediatrician in consultation with a haematologist will be best suited to implement these recommendations given the complexity of the care involved in children with VTE.</p>
      </div>

      <div class="gps-card">
        <div class="gps-label">Good Practice Statement 2 ‚Äî High Bleeding Risk: Prefer Short Half-Life Agents</div>
        <p class="gps-text">For paediatric patients who are at high risk of bleeding (e.g., CSVT and associated haemorrhage secondary to venous congestion, immediately after or anticipated invasive procedures), consider the use of a short half-life agent such as UFH rather than LMWH or DOACs if anticoagulation is needed, to decrease the risk of worsening haemorrhage or bleeds.</p>
      </div>
    </section>

    <!-- CLINICAL ALGORITHMS -->

    <!-- RECOMMENDATIONS -->
    <section id="recommendations" class="page-section">
      <h2 class="section-title"><span class="section-icon">üìå</span> Recommendations (1‚Äì20)</h2>
      <p style="font-size:0.82rem; color:#555; margin-bottom:1rem;">Click any card to expand. Use the toggle bar above to show/hide Evidence Detail, Implementation notes, or Quick View (action steps only).</p>
      <div id="no-results">No recommendations match your search. Try different terms.</div>


      <!-- REC 1 -->
      <div class="rec-card cat-dvt-pe" id="rec1">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 1</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Symptomatic DVT or PE ‚Äî Anticoagulation vs No Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with symptomatic DVT or PE, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            For paediatric patients with symptomatic DVT or PE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation rather than no anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol class="checklist" style="list-style:decimal; padding-left:1.5rem;">
                <li>Confirm diagnosis of symptomatic DVT or PE</li>
                <li>Exclude specific scenarios where anticoagulation benefit is uncertain (neonatal CVAD-associated VTE; trauma-associated VTE)</li>
                <li>Initiate anticoagulation ‚Äî select agent per Recs 17‚Äì20 (DOACs preferred if eligible)</li>
                <li>Determine duration based on VTE type (Recs 3 or 4)</li>
                <li>Involve paediatric haematologist (GPS 1)</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec1-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec1-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec1-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec1-applies" class="panel-content active">
              <p class="panel-heading">Population &amp; Exceptions</p>
              <p><strong>Applies to:</strong> Paediatric patients (all ages) with symptomatic DVT or PE</p>
              <p><strong>Exclusions / Uncertain benefit ‚Äî panel NOT confident recommendation applies to:</strong></p>
              <ul>
                <li>Neonates with central venous catheter (CVAD)-associated VTE ‚Äî may not benefit or may be harmed</li>
                <li>Trauma-associated VTE ‚Äî anticoagulation may result in no significant benefit or increased harm</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Note:</strong> EINSTEIN-Junior and DIVERSITY eligibility criteria were restrictive ‚Äî results not generalisable to all paediatric patients (e.g., excluded age &lt;6 months, low birth weight, severe liver/renal impairment).</p>
            </div>
            <div id="rec1-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6;">
                <li>Confirm diagnosis of symptomatic DVT or PE</li>
                <li>Check for neonatal CVAD-associated VTE or trauma-associated VTE (individualise if present)</li>
                <li>Initiate anticoagulation ‚Äî refer to Recs 17‚Äì20 for agent selection (DOACs preferred)</li>
                <li>Determine duration (Rec 3 for provoked; Rec 4 for unprovoked)</li>
                <li>Arrange monitoring per chosen agent</li>
                <li>Involve paediatric haematologist (GPS 1)</li>
              </ol>
            </div>
            <div id="rec1-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Major bleeding: EINSTEIN-Junior + DIVERSITY: 8/767 (1.0%) major bleeds; 14/767 (1.8%) CRNMB</li>
                <li>NEOCLOT: 2/33 (6.1%) major bleeding and 1/33 (3.0%) CRNMB in anticoagulated neonates/infants</li>
                <li>Trauma study: mortality 1/31 (3.2%) anticoagulation vs 0/10 (0%) no anticoagulation</li>
                <li>Neonates generally at higher bleeding risk</li>
                <li>High bleeding risk situations: consider short half-life agent UFH (GPS 2)</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0; border-color:var(--clr-border);">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>2 RCTs: EINSTEIN-Junior (n=500; age &gt;37wk GA to 17y) and DIVERSITY (n=267; age &gt;37wk GA to &lt;18y) ‚Äî DOACs vs SOC; neither included a no-anticoagulation arm</li>
                <li>Retrospective multicenter observational study n=346 (neonates, infants, children &lt;2y with VTE)</li>
                <li>NEOCLOT prospective multicenter study n=115 (neonates/infants ‚â§6mo with CVAD-associated VTE)</li>
                <li>Single-centre retrospective n=753 (paediatric patients with trauma-associated VTE)</li>
                <li>Benefits: 7/223 (3.1%) receiving anticoagulation had recurrent VTE vs 4/47 (8.5%) without (RR 0.38; 95% CI 0.12‚Äì1.3)</li>
                <li>NEOCLOT: 21/24 (87.5%) receiving anticoagulation had thrombus resolution vs 11/13 (84.6%) not; 8/25 (32.1%) not anticoagulated had thrombus extension</li>
                <li>Certainty: very low (serious risk of bias, serious imprecision)</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div><strong>Research Needs:</strong> Study of paediatric patients with malignancy and thrombosis; separate reporting of symptomatic vs clinically unsuspected VTE; risk stratification of subgroups; real-world DOAC data</div>
              </div>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0; border-color:var(--clr-border);">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>Strong indirect evidence from adults underpins this recommendation despite limited direct paediatric data</li>
                <li>For most paediatric patients with symptomatic DVT/PE, anticoagulation is warranted</li>
                <li>For neonatal CVAD-associated VTE: individuaise ‚Äî observational studies suggest possible lack of benefit or harm</li>
                <li>For trauma-associated VTE: consider carefully ‚Äî retrospective study suggests no benefit and possible increased harm</li>
                <li>Enrol patients in registries or clinical trials where possible</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 2 -->
      <div class="rec-card cat-dvt-pe" id="rec2">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 2</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Clinically Unsuspected (Asymptomatic) DVT or PE ‚Äî Anticoagulation vs No Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with clinically unsuspected (previously termed asymptomatic) DVT or PE, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            For paediatric patients with clinically unsuspected (previously termed asymptomatic) DVT or PE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> either using anticoagulation or no anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout info">
            <span class="callout-icon">‚Ñπ</span>
            <div>This is an <strong>"either/or" conditional recommendation</strong> ‚Äî no preference for treating or not treating. Decision must be individualised for each patient.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm incidental/clinically unsuspected VTE finding</li>
                <li>Assess patient subpopulation (neonates, cardiac disease, critically ill, trauma)</li>
                <li>Individualise decision to treat or not treat based on risk-benefit assessment</li>
                <li>If treating, select agent per Recs 17‚Äì20</li>
                <li>If not treating, arrange monitoring for thrombus extension/symptom development</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec2-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec2-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec2-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec2-applies" class="panel-content active">
              <p class="panel-heading">Population</p>
              <p><strong>Applies to:</strong> Any paediatric patient in whom DVT or PE is detected incidentally (clinically unsuspected / previously termed asymptomatic)</p>
              <p><strong>Subpopulations where benefits/harms vary:</strong></p>
              <ul>
                <li>Neonates with CVAD-related VTE</li>
                <li>Critically ill neonates</li>
                <li>Patients with cardiac disease</li>
                <li>Patients who have experienced trauma</li>
              </ul>
              <p><strong>Natural history:</strong> Clinically unsuspected DVT/PE carries lower risk of acute and long-term sequelae than symptomatic VTE, especially in certain subpopulations.</p>
            </div>
            <div id="rec2-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm clinically unsuspected VTE ‚Äî distinguish from symptomatic</li>
                <li>Review subpopulation (neonates/cardiac/trauma/critically ill)</li>
                <li>Weigh benefits (preventing extension, organ complications) vs harms (bleeding)</li>
                <li>Make individualised decision with patient/family shared decision-making</li>
                <li>If treating: select agent (Recs 17‚Äì20); determine duration (Recs 3‚Äì4)</li>
                <li>If not treating: schedule follow-up imaging; monitor for symptoms</li>
                <li>Involve paediatric haematologist (GPS 1)</li>
              </ol>
            </div>
            <div id="rec2-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Major bleeding in 1/3 (33.3%) patients receiving anticoagulation for asymptomatic VTE (very small study)</li>
                <li>Mortality: 1/13 (7.7%) anticoagulation vs 0/9 (0.0%) no anticoagulation (very small study)</li>
                <li>PTS risk 21.4% at 13 months in trauma patients; 16.6% in asymptomatic CVAD-related VTE at 2 years</li>
                <li>EINSTEIN-Junior and DIVERSITY did NOT separately report outcomes for symptomatic vs unsuspected</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>3 studies (1 single-arm non-comparative, 1 observational non-randomised, 1 retrospective comparative); total &lt;100 patients</li>
                <li>Thrombus extension: 0/1 (0.0%) anticoagulation vs 2/5 (40.0%); resolution 9/13 (69.2%) vs 1/1 (100.0%); recurrence 0/1 (0.0%) vs 0/3 (0%)</li>
                <li>Certainty: very low (serious risk of bias and very serious imprecision)</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div><strong>Research Needs:</strong> Outcomes of clinically unsuspected VTE in cancer, short gut, end-stage renal disease, long-term central lines; consistent use of international standard definitions; separate presentation of symptomatic vs unsuspected outcomes in future trials</div>
              </div>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>No routine screening for clinically unsuspected VTE is recommended</li>
                <li>If unsuspected VTE is detected, individualise the decision</li>
                <li>Single institution observational retrospective studies suggest not treating does not lead to severe outcomes in select subpopulations</li>
                <li>Use shared decision-making with patient/family regarding treatment vs surveillance</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 3 -->
      <div class="rec-card cat-dvt-pe" id="rec3">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 3</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Provoked VTE ‚Äî Duration: 6 Weeks vs 3 Months (Kids-DOTT)</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with provoked VTE, should anticoagulation for 6 weeks vs 3 months be used?</div>
          <div class="rec-statement">
            For <strong>select</strong> paediatric patients with provoked VTE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> 6 weeks rather than 3 months of anticoagulation. Exclusions to this recommendation include (1) PE, (2) recurrent VTE, (3) persistent occlusive thrombus at 6 weeks, (4) cancer-associated thrombosis, (5) patients with persistent antiphospholipid antibodies (APAs) or major thrombophilia, and (6) ongoing VTE risk factors (conditional recommendation based on very low certainty in the evidence of effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout info">
            <span class="callout-icon">‚Ñπ</span>
            <div><strong>Based on Kids-DOTT RCT</strong> ‚Äî First RCT to evaluate duration of anticoagulation in paediatric provoked VTE. Strict eligibility criteria apply; results cannot be extrapolated beyond the studied population.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Kids-DOTT Eligibility Checklist ‚Äî All Must Be Met for 6-Week Treatment</p>
              <ul class="checklist">
                <li class="check">First episode provoked VTE</li>
                <li class="cross">NOT PE</li>
                <li class="cross">NOT recurrent VTE</li>
                <li class="cross">NOT persistently occlusive thrombus at 6 weeks</li>
                <li class="cross">NOT cancer-associated thrombosis</li>
                <li class="cross">NOT positive APA at 6 weeks (re-test if elevated at diagnosis)</li>
                <li class="cross">NOT major thrombophilia</li>
                <li class="cross">NOT ongoing VTE risk factors</li>
                <li class="cross">NOT active cancer, SLE, proximal PE, or requiring thrombolysis (Kids-DOTT exclusions)</li>
              </ul>
              <p style="font-size:0.78rem; margin-top:0.5rem; color:#555;">If ANY exclusion criterion is met ‚Üí use 3 months anticoagulation. For persistent provoking risk factors ‚Üí longer duration may be considered.</p>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec3-eligibility')">Eligibility Criteria</button>
              <button class="panel-tab" onclick="switchTab(this,'rec3-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec3-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec3-eligibility" class="panel-content active">
              <p class="panel-heading">Who Qualifies for 6-Week Duration (Strict Kids-DOTT Criteria)</p>
              <p><strong>All criteria must be met:</strong></p>
              <ul class="checklist">
                <li class="check">First episode provoked VTE</li>
                <li class="cross">NOT PE</li>
                <li class="cross">NOT recurrent VTE</li>
                <li class="cross">NOT persistently occlusive thrombus at 6-week imaging</li>
                <li class="cross">NOT cancer-associated thrombosis</li>
                <li class="cross">NOT positive APA at 6 weeks (re-test if elevated at diagnosis)</li>
                <li class="cross">NOT major thrombophilia</li>
                <li class="cross">NOT ongoing VTE risk factors</li>
                <li class="cross">NOT active cancer, SLE, proximal PE, or requiring thrombolysis</li>
              </ul>
              <p style="margin-top:0.5rem; font-size:0.8rem;"><strong>Does NOT meet criteria:</strong> Use 3 months anticoagulation<br>
              <strong>Persistent provoking risk factors:</strong> Longer duration may be considered</p>
              <p style="font-size:0.78rem; margin-top:0.5rem; color:#666;"><strong>Most common provoking factors in Kids-DOTT:</strong> CVAD (52%), infection (34%), surgery/trauma (20%); &gt;85% received LMWH</p>
            </div>
            <div id="rec3-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm first-episode provoked VTE (not PE, not recurrent)</li>
                <li>Test APA at diagnosis; plan re-test at 6 weeks if initially elevated</li>
                <li>Initiate anticoagulation (refer to Recs 17‚Äì20 for agent)</li>
                <li>At 6 weeks: repeat imaging to assess thrombus resolution</li>
                <li>Re-test APA at 6 weeks if initially positive</li>
                <li>If thrombus resolved, APA negative, and all other criteria met ‚Üí stop anticoagulation at 6 weeks</li>
                <li>If persistent occlusive thrombus, APA positive, or other exclusion criterion ‚Üí continue to 3 months</li>
                <li>Assess for ongoing VTE risk factors ‚Üí if present, consider longer duration</li>
              </ol>
            </div>
            <div id="rec3-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Kids-DOTT: symptomatic recurrent VTE 1/154 (0.6%) 6-week vs 2/143 (1.4%) 3-month ‚Äî non-inferior</li>
                <li>No difference in mortality (4/206 [1.9%] vs 4/206 [1.9%])</li>
                <li>Kids-DOTT was NOT powered to detect small differences in recurrence</li>
                <li><strong>Critical:</strong> Cannot extrapolate beyond Kids-DOTT inclusion criteria ‚Äî many paediatric patients with provoked VTE were excluded from the trial</li>
                <li>Certainty very low despite RCT: serious imprecision</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li><strong>Kids-DOTT RCT</strong> (n=417 randomised; 297 per-protocol): first RCT evaluating duration; demonstrated non-inferiority of 6 weeks vs 3 months for recurrent VTE and clinically relevant bleeding</li>
                <li>Single-centre retrospective cohort (n=74, CVAD-related VTE): 39 patients treated shorter duration ‚Äî no inferior outcomes</li>
                <li>Retrospective cohort (n=23, rivaroxaban 6w/3m/6m) ‚Äî no recurrent VTE or relevant bleeding</li>
                <li>Kids-DOTT excluded: active cancer, major thrombophilia, SLE, proximal PE, patients requiring thrombolysis</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div><strong>Research Needs:</strong> Whether 6-week shortening applies to patients with occlusive thrombus at 6 weeks; further investigation of thrombus resolution at 6 weeks as a decision criterion</div>
              </div>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>6-week imaging to assess thrombus occlusion is essential to determine eligibility for stopping</li>
                <li>APA testing: required at diagnosis and again at 6 weeks if initially elevated</li>
                <li>CVAD removal may affect thrombus resolution ‚Äî consider CVAD status in duration decision</li>
                <li>Anticoagulation agent used in Kids-DOTT was predominantly LMWH (&gt;85%) ‚Äî evidence for 6-week shortening specifically with DOACs less direct</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 4 -->
      <div class="rec-card cat-dvt-pe" id="rec4">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 4</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Unprovoked DVT or PE ‚Äî Duration: 6‚Äì12 Months vs Indefinite</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with unprovoked DVT or PE, should anticoagulation for 6 to 12 months vs indefinite anticoagulation be used?</div>
          <div class="rec-statement">
            For paediatric patients with unprovoked DVT or PE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation for 6 to 12 months rather than indefinite anticoagulation (conditional recommendation based on very low certainty in the evidence of effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout warning">
            <span class="callout-icon">‚ö†</span>
            <div><strong>Adult data extrapolation:</strong> No paediatric studies evaluate treatment duration for unprovoked VTE. This recommendation draws on adult evidence. The panel considered that indefinite anticoagulation would more negatively affect QOL in younger patients than adults.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm unprovoked VTE (no identifiable provoking factor)</li>
                <li>Complete thrombophilia screen</li>
                <li>Initiate anticoagulation ‚Äî select agent per Recs 17‚Äì20</li>
                <li>Plan for 6‚Äì12 months total duration</li>
                <li>Consider patient values, preferences, and QOL in duration decision</li>
                <li>Discuss risks of recurrence (21‚Äì36% at 3.5 years) with patient/family</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec4-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec4-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec4-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec4-applies" class="panel-content active">
              <p class="panel-heading">Population</p>
              <p><strong>Applies to:</strong> Paediatric patients with unprovoked DVT or PE (no identifiable provoking factor)</p>
              <p><strong>Higher recurrence risk:</strong></p>
              <ul>
                <li>Age &gt;12 years at index VTE</li>
                <li>Inherited thrombophilia</li>
                <li>Recurrence rates 21%‚Äì36% at 3.5 years in paediatric patients aged &gt;1 year with unprovoked VTE</li>
              </ul>
              <p><strong>Note:</strong> Unprovoked VTE is rare in paediatrics. Patient values and preferences should be central to the decision.</p>
            </div>
            <div id="rec4-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm unprovoked VTE</li>
                <li>Thrombophilia screen (including APA, factor V Leiden, prothrombin gene mutation, protein C/S/AT)</li>
                <li>Initiate anticoagulation ‚Äî agent per Recs 17‚Äì20</li>
                <li>Target 6‚Äì12 months total duration</li>
                <li>Assess thrombophilia results and anatomical risk factors during treatment</li>
                <li>Discuss recurrence risk (21‚Äì36% at 3.5 years in children aged &gt;1 year)</li>
                <li>Shared decision-making re: extended vs stopping at 6‚Äì12 months</li>
                <li>If persistent risk factors: consider longer duration (individualise)</li>
              </ol>
            </div>
            <div id="rec4-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Adult evidence: indefinite anticoagulation significantly reduces PE (RR 0.29) and DVT (RR 0.20) ‚Äî high-certainty evidence in adults</li>
                <li>But: indefinite anticoagulation increases major bleeding (RR 2.17; 95% CI 1.20‚Äì3.35 ‚Äî high-certainty in adults)</li>
                <li>In paediatric patients: additional impact on QOL (no injections, no monitoring, ability to participate in activities)</li>
                <li>No direct paediatric RCT evidence exists for this PICO question</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>No new paediatric studies since 2018 evaluating treatment duration in unprovoked VTE</li>
                <li>Adult ASH 2020 meta-analysis: indefinite anticoagulation reduces VTE recurrence significantly ‚Äî high certainty; increases major bleeding ‚Äî high certainty</li>
                <li>Paediatric observational data: recurrence 21%‚Äì36% at 3.5 years in patients aged &gt;1 year</li>
                <li>Certainty for paediatric population: very low; extrapolation from adults is problematic</li>
              </ul>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>No robust paediatric evidence exists ‚Äî treatment decision is largely value-based and clinical judgement</li>
                <li>Strongly recommend paediatric haematology involvement for all patients with unprovoked VTE</li>
                <li>Anatomical abnormalities (e.g., May-Thurner, nutcracker) may be relevant to recurrence risk and should be sought</li>
                <li>Thrombophilia results should be considered but currently evidence for changing duration based on specific thrombophilia is limited in paediatric patients</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 5 -->
      <div class="rec-card cat-csvt" id="rec5">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 5</div>
          <div class="rec-title-block">
            <div class="rec-short-title">CSVT ‚Äî Anticoagulation vs No Anticoagulation (incl. with Haemorrhage)</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low (Paediatric Data)</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with CSVT, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            For paediatric patients with cerebral sinus venous thrombosis (CSVT) with and without haemorrhage secondary to venous congestion, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation rather than no anticoagulation (conditional recommendation based on very low certainty in the evidence based on paediatric data <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout danger">
            <span class="callout-icon">üö®</span>
            <div><strong>Do NOT withhold anticoagulation</strong> for haemorrhage due to venous congestion (thrombus obstruction) in CSVT. Evidence of venous congestion with or without haemorrhage should be managed with anticoagulation.</div>
          </div>
          <div class="callout warning">
            <span class="callout-icon">‚ö†</span>
            <div><strong>Downgraded from 2018:</strong> The 2018 guideline made this a STRONG recommendation. The 2024 update downgrades it to <strong>conditional</strong> based on paediatric-specific data review.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm CSVT diagnosis</li>
                <li>Determine aetiology of any haemorrhage ‚Äî is it secondary to venous congestion? ‚Üí YES: anticoagulate; NO: individualise</li>
                <li>Assess underlying aetiology (infection, trauma, cancer) and treat appropriately (including surgical if infection-associated)</li>
                <li>Initiate anticoagulation ‚Äî consider UFH if high bleeding risk (GPS 2)</li>
                <li>Monitor for neurologic deterioration</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec5-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec5-nuances')">Key Nuances</button>
              <button class="panel-tab" onclick="switchTab(this,'rec5-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec5-applies" class="panel-content active">
              <p class="panel-heading">Population</p>
              <p><strong>Applies to:</strong> All paediatric patients with CSVT ‚Äî with or without haemorrhage secondary to venous congestion</p>
              <p><strong>Key nuances by subgroup:</strong></p>
              <ul>
                <li><strong>Haemorrhage DUE TO venous congestion:</strong> ANTICOAGULATE ‚Äî do not withhold</li>
                <li><strong>Haemorrhage from other aetiology:</strong> Individualise carefully</li>
                <li><strong>Intracranial haemorrhage unrelated to CSVT:</strong> Do not automatically anticoagulate</li>
                <li><strong>Premature neonates with IVH:</strong> Higher bleeding risk ‚Äî careful individual assessment</li>
                <li><strong>Infection-associated CSVT:</strong> Also treat underlying infection (surgical intervention if needed)</li>
                <li><strong>Cavernous sinus thrombosis:</strong> Panel notes anticoagulation if no contraindications (pathophysiology may differ)</li>
              </ul>
            </div>
            <div id="rec5-nuances" class="panel-content">
              <p class="panel-heading">Key Clinical Nuances</p>
              <ul>
                <li>Evidence of venous congestion secondary to thrombus obstruction ‚Äî with OR without haemorrhage ‚Äî should be managed with anticoagulation</li>
                <li>Different populations may have different risks: neonates, infection-associated, trauma, surgery, cancer</li>
                <li>High bleeding risk: prefer short half-life agent (UFH) over LMWH or DOACs (GPS 2)</li>
                <li>Ensure appropriate treatment for associated conditions (e.g., surgical drainage for infection-associated CSVT)</li>
                <li>If neurologic deterioration despite anticoagulation ‚Üí consider thrombolysis/reperfusion (Rec 6)</li>
                <li>Cavernous sinus thrombosis: anticoagulate if no contraindications</li>
              </ul>
            </div>
            <div id="rec5-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Bleeding: 3/64 (4.7%) anticoagulation vs 1/31 (3.2%) no anticoagulation (not significantly different)</li>
                <li>Pooled RR of bleeding 1.90 (95% CI 0.27‚Äì13.31) ‚Äî very wide confidence intervals</li>
                <li>EINSTEIN-Junior CSVT substudy: 6/114 (5.4%) total bleeding (1 major, 5 CRNMBs)</li>
                <li>Premature neonates with IVH: significantly higher bleeding risk</li>
                <li>Caution in patients with absolute contraindications to anticoagulation</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>9 paediatric studies encompassing &gt;700 paediatric patients; neonates to adolescents aged 18 years</li>
                <li>Mortality: anticoagulation 5/366 (1.4%) vs no anticoagulation 9/82 (11.0%); RR 0.12 (95% CI 0.04‚Äì0.36)</li>
                <li>Neurologic deficit: RR 0.95 (95% CI 0.69‚Äì1.30) ‚Äî no significant difference</li>
                <li>Thrombus resolution: 64/79 (78%) with anticoagulation had partial or complete resolution vs 38/71 (53.5%) without (RR 1.5; 95% CI 1.2‚Äì1.9)</li>
                <li>Recurrence: relative effects not estimable (no events reported)</li>
                <li>Certainty very low: risk of bias and confounding</li>
                <li>Panel downgraded from strong (2018) to conditional (2024)</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div><strong>Research Needs:</strong> Impact of degree of CSVT resolution/recanalisation on neurological outcomes; further studies on harms/benefits in subgroups; efficacy and safety of thrombolysis in paediatric CSVT management</div>
              </div>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>Use UFH rather than LMWH or DOACs in high bleeding risk scenarios for easier reversal (GPS 2)</li>
                <li>Neuroimaging to distinguish haemorrhage secondary to venous congestion vs other causes is essential</li>
                <li>Duration of anticoagulation in CSVT: generally 3‚Äì6 months (per earlier guidelines, individual assessment)</li>
                <li>Follow-up neuroimaging to assess thrombus resolution</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 6 -->
      <div class="rec-card cat-csvt" id="rec6">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 6</div>
          <div class="rec-title-block">
            <div class="rec-short-title">CSVT ‚Äî Anticoagulation Alone vs Thrombolysis + Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with CSVT, should thrombolysis followed by anticoagulation vs anticoagulation alone be used?</div>
          <div class="rec-statement">
            For paediatric patients with CSVT, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation alone rather than thrombolysis followed by anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Initiate anticoagulation (per Rec 5)</li>
                <li>Use anticoagulation alone as first-line ‚Äî do NOT routinely add thrombolysis</li>
                <li>Monitor closely for neurologic deterioration or evidence of ischaemia</li>
                <li>If deterioration despite anticoagulation: consider thrombolysis/reperfusion if resources available and patient/family accept risks</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec6-applies')">When Thrombolysis May Be Considered</button>
              <button class="panel-tab" onclick="switchTab(this,'rec6-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec6-applies" class="panel-content active">
              <p class="panel-heading">Exceptions ‚Äî When Thrombolysis May Be Considered</p>
              <ul>
                <li>Neurologic deterioration despite anticoagulation</li>
                <li>Evidence of ischaemia</li>
                <li>Availability of paediatric interventional radiology resources</li>
                <li>Patient/family acceptability of anticipated risks and benefits</li>
              </ul>
              <p><strong>Note:</strong> Adult RCT of endovascular treatment did NOT show benefit vs anticoagulation alone; higher mortality in endovascular arm. Endovascular options depend on patient size and institutional resources.</p>
            </div>
            <div id="rec6-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>No randomised trial for thrombolysis in paediatric CSVT</li>
                <li>Adult RCT: endovascular treatment did NOT show benefit; higher mortality in endovascular arm</li>
                <li>Evidence is sparse ‚Äî balance of benefits and harms of thrombolysis uncertain in paediatrics</li>
                <li>Reperfusion therapies may be considered in neurologic deterioration depending on local resources</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>No new paediatric data for this recommendation in the 2024 update</li>
                <li>28 observational studies from original guidelines + 2 new (1 on neonates with RAT; 1 on RAT in paediatric patients on haemodialysis)</li>
                <li>No randomised trial for thrombolysis in paediatric CSVT</li>
                <li>Adult RCT: endovascular treatment did NOT show benefit vs anticoagulation alone ‚Äî higher mortality in endovascular arm</li>
                <li>Certainty: very low</li>
              </ul>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>Thrombolysis is NOT routinely recommended ‚Äî reserve for select cases with neurologic deterioration</li>
                <li>Access to paediatric interventional radiology is needed for catheter-directed thrombolysis</li>
                <li>Document careful risk-benefit discussion with patient/family before considering thrombolysis</li>
              </ul>
            </div>
          </div>
        </div>
      </div>


      <!-- REC 7 (7a and 7b) -->
      <div class="rec-card cat-rat" id="rec7">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 7a/b</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Right Atrial Thrombosis (RAT) ‚Äî Anticoagulation vs No Anticoagulation (Risk Stratification)</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For neonatal and paediatric patients with RAT, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            <strong>Rec 7a (High-Risk Features Present):</strong> For neonates and paediatric patients with RAT, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> anticoagulation rather than no anticoagulation for patients with high-risk features and low perceived risk of bleeding (conditional recommendation based on very low certainty ‚äï‚óã‚óã‚óã).
          </div>
          <div class="rec-statement">
            <strong>Rec 7b (High-Risk Features Absent):</strong> For neonates and paediatric patients with RAT and the absence of high-risk features or with unacceptable perceived risk of bleeding, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> no anticoagulation over anticoagulation (conditional recommendation based on very low certainty ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">RAT Risk Stratification ‚Äî Quick Guide</p>
              <p style="font-size:0.8rem; font-weight:700; margin-bottom:0.25rem; color:var(--clr-accent);">HIGH-RISK features (any = consider anticoagulation if bleeding risk acceptable):</p>
              <ul style="font-size:0.8rem; line-height:1.5;">
                <li>Large size (&gt;2 cm or &gt;50% of right atrium)</li>
                <li>Snake-shaped or pedunculated morphology</li>
                <li>Mobile thrombus</li>
                <li>Involving tricuspid valve / restricting blood flow</li>
                <li>Intracardiac right-to-left shunt / patent foramen ovale</li>
                <li>Associated CVAD</li>
                <li>Symptoms: arrhythmias, haemodynamic compromise, emboli</li>
                <li>Increasing size despite therapeutic anticoagulation</li>
              </ul>
              <p style="font-size:0.8rem; font-weight:700; margin-top:0.5rem; color:var(--clr-success);">NO high-risk features ‚Üí NO anticoagulation + close radiological reassessment within 3 days</p>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec7-highrisk')">High-Risk Features</button>
              <button class="panel-tab" onclick="switchTab(this,'rec7-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec7-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec7-highrisk" class="panel-content active">
              <p class="panel-heading">High-Risk Features of RAT (from Guideline)</p>
              <p><strong>Any of the following should prompt consideration of anticoagulation (if bleeding risk acceptable):</strong></p>
              <ul>
                <li>Large size (&gt;2 cm in any dimension or &gt;50% of right atrium)</li>
                <li>Snake-shaped morphology</li>
                <li>Pedunculated morphology</li>
                <li>Mobile thrombus</li>
                <li>Location involving tricuspid valve or restricting blood flow</li>
                <li>Presence of intracardiac right-to-left shunt or patent foramen ovale</li>
                <li>Concomitant cardiac anomalies (decreased function, abnormal rhythm, pacemaker/ICD)</li>
                <li>Presence of CVAD and location of thrombus relative to catheter</li>
                <li>Symptoms: arrhythmias, emboli, haemodynamic compromise</li>
                <li>Age of thrombus (fresh vs chronic)</li>
                <li>Increasing size despite therapeutic anticoagulation</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>NEOCLOT high-risk criteria:</strong> Size &gt;50% of right atrium; restricting tricuspid valve; extension through tricuspid valve or PFO; haemodynamic instability; pedunculated/mobile/snake-shaped; increasing despite therapeutic anticoagulation</p>
              <p style="margin-top:0.5rem;"><strong>Without high-risk features:</strong> Wait-and-see approach with close radiological reassessment (&lt;3 days) ‚Äî not associated with higher risk of adverse outcomes</p>
            </div>
            <div id="rec7-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm RAT diagnosis by echocardiography</li>
                <li>Characterise morphology: size, shape (pedunculated/mobile/snake-shaped), location relative to tricuspid valve</li>
                <li>Assess for cardiac shunts (PFO, ASD, etc)</li>
                <li>Assess haemodynamic status and symptoms</li>
                <li>Determine bleeding risk</li>
                <li>If high-risk features present AND bleeding risk acceptable ‚Üí initiate anticoagulation (agent per Recs 17‚Äì20)</li>
                <li>If no high-risk features OR unacceptable bleeding risk ‚Üí withhold anticoagulation; arrange echocardiographic reassessment within 3 days</li>
                <li>If increasing despite anticoagulation ‚Üí reassess urgently; may trigger step-up therapy</li>
              </ol>
            </div>
            <div id="rec7-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Resolution rates: 32/42 (76.2%) anticoagulation vs 23/25 (92.0%) no anticoagulation ‚Äî no clear benefit of anticoagulation in low-risk RAT</li>
                <li>Recurrence: 1/16 (6.3%) anticoagulation vs 1/25 (4.0%) no anticoagulation ‚Äî similar</li>
                <li>Bleeding: 9/31 (29%) in anticoagulation group; 2 deaths deemed related to anticoagulation; 0/4 (0%) in no-anticoagulation group died</li>
                <li>Major bleeding/unspecified: 3/41 (7.3%) and 7/46 (15.2%) anticoagulation; 0/25 (0.0%) no anticoagulation</li>
                <li>Evidence is sparse, non-randomised, and subject to significant bias</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>No new data for recommendation 7 in this update</li>
                <li>28 observational studies from original guidelines + 2 additional (1 on neonates with RAT; 1 on RAT in paediatric patients on chronic haemodialysis)</li>
                <li>Studies are non-randomised, small, and subject to significant bias</li>
                <li>Insufficient data for formal risk stratification of RAT and bleeding from anticoagulation</li>
                <li>Certainty: very low (serious risk of bias and very serious imprecision)</li>
              </ul>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>Echocardiographic characterisation is essential before treatment decision</li>
                <li>Decisions should be individualised and made with the paediatric cardiology team</li>
                <li>Radiological reassessment within 3 days is required for conservatively managed patients</li>
                <li>Document rationale for treatment vs no treatment clearly</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 8 -->
      <div class="rec-card cat-rat" id="rec8">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 8</div>
          <div class="rec-title-block">
            <div class="rec-short-title">RAT Requiring Treatment ‚Äî Anticoagulation Alone vs Thrombolysis + Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For neonatal and paediatric patients with RAT, should thrombolysis followed by anticoagulation vs anticoagulation alone be used?</div>
          <div class="rec-statement">
            For neonates and paediatric patients with RAT requiring antithrombotic treatment, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation alone over thrombolysis followed by anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>For RAT requiring treatment (high-risk features per Rec 7a): use anticoagulation alone as first-line</li>
                <li>Do NOT routinely add thrombolysis</li>
                <li>Reserve thrombolysis for exceptional cases where haemodynamic status, size, and mobility of thrombus dictate more aggressive therapy</li>
                <li>If considering thrombolysis: assess feasibility and patient/family acceptability of risks and benefits</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec8-remarks')">Remarks</button>
              <button class="panel-tab" onclick="switchTab(this,'rec8-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec8-remarks" class="panel-content active">
              <p class="panel-heading">Key Remarks</p>
              <ul>
                <li>In most cases, anticoagulation alone is adequate for RAT requiring treatment</li>
                <li>Individual cases may exist where haemodynamic status, size, and mobility dictate more aggressive therapy</li>
                <li>Choice to use thrombolysis depends on: feasibility of intervention; patient and family acceptability; anticipated risks and benefits</li>
                <li>Thrombolysis data for RAT: resolution 16/17 (94.1%) thrombolysis vs 25/27 (92.6%) anticoagulation alone ‚Äî no benefit of thrombolysis</li>
                <li>Thrombolysis deaths: 2/11 (18.2%) patients; bleeding 3/10 (30.0%) and 1/6 (16.7%)</li>
              </ul>
            </div>
            <div id="rec8-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Thrombolysis bleeding: 3/10 (30.0%) and 1/6 (16.7%)</li>
                <li>Thrombolysis mortality: 2/11 (18.2%) patients treated with thrombolysis followed by anticoagulation died</li>
                <li>Resolution rates similar between thrombolysis and anticoagulation alone ‚Äî no clear benefit</li>
                <li>Neonates particularly vulnerable to intracranial haemorrhage with thrombolysis</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>No new data for recommendation 8 in this update</li>
                <li>From original 28 observational studies: thrombolysis 2/11 (18.2%) patients died; resolution: 16/17 (94.1%) thrombolysis vs 25/27 (92.6%) anticoagulation alone</li>
                <li>Bleeding for thrombolysis: 3/10 (30.0%) and 1/6 (16.7%)</li>
                <li>Certainty: very low</li>
              </ul>
            </div>
            <div class="impl-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Implementation Notes</p>
              <ul>
                <li>Document rationale carefully if thrombolysis is considered for RAT</li>
                <li>Paediatric cardiology input is essential</li>
                <li>Surgical thrombectomy: not addressed in this recommendation but may be considered in extreme circumstances ‚Äî refer to specialist centre</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 9 -->
      <div class="rec-card cat-rvt" id="rec9">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 9</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Neonatal RVT ‚Äî Anticoagulation vs No Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For neonates with RVT, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            For neonates with renal vein thrombosis (RVT), the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation rather than no anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm neonatal RVT diagnosis (ultrasound +/‚àí Doppler)</li>
                <li>Assess laterality (unilateral vs bilateral) ‚Äî critical for Rec 10 decision</li>
                <li>Assess gestational age, IVH, comorbidities, degree of thrombocytopenia</li>
                <li>Initiate anticoagulation (weigh against bleeding risk)</li>
                <li>Plan long-term follow-up: blood pressure, renal function, kidney atrophy</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec9-remarks')">Remarks &amp; Rationale</button>
              <button class="panel-tab" onclick="switchTab(this,'rec9-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec9-remarks" class="panel-content active">
              <p class="panel-heading">Remarks &amp; Clinical Rationale</p>
              <ul>
                <li>Panel considers anticoagulation to have potential beneficial effect on long-term outcomes: avoiding hypertension, chronic kidney disease, and renal failure</li>
                <li>Anticoagulation likely more important with <strong>bilateral</strong> renal vein involvement compared with unilateral (with or without IVC extension)</li>
                <li>Individual bleeding risk assessment required: gestational age, presence of IVH, underlying comorbidities, thrombocytopenia</li>
                <li>Outcomes of interest: renal function, blood pressure, kidney atrophy, renal failure</li>
              </ul>
            </div>
            <div id="rec9-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Neonates have highest bleeding risk in the paediatric spectrum</li>
                <li>Gestational age affects pharmacokinetics and bleeding risk significantly</li>
                <li>Intraventricular haemorrhage (IVH): if present, markedly increases risk of anticoagulation-related intracranial bleeding</li>
                <li>Thrombocytopenia: increases bleeding risk; assess before anticoagulation</li>
                <li>Short half-life agent (UFH) preferred if high bleeding risk (GPS 2)</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>Evidence derived from observational studies only</li>
                <li>Critically ill patients who received thrombolysis cannot be adequately compared to those who received anticoagulation alone due to selection bias</li>
                <li>Certainty: very low</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 10 (10a and 10b) -->
      <div class="rec-card cat-rvt strong-rec-highlight" id="rec10">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 10a/b</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Neonatal RVT ‚Äî Thrombolysis + Anticoagulation vs Anticoagulation Alone (Non-life-threatening vs Life-threatening)</div>
            <div class="rec-badges">
              <span class="badge badge-strong">‚¨õ STRONG (10a)</span>
              <span class="badge badge-conditional">Conditional (10b)</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For neonates with RVT, should thrombolysis followed by anticoagulation vs anticoagulation alone be used?</div>

          <div class="callout success">
            <span class="callout-icon">‚úì</span>
            <div><strong>Rec 10a is the ONLY STRONG recommendation in the entire guideline.</strong> For non-life-threatening neonatal RVT ‚Äî STRONG recommendation AGAINST thrombolysis (anticoagulation alone).</div>
          </div>

          <div class="rec-statement">
            <strong>Rec 10a ‚Äî Non-Life-Threatening RVT (unilateral or unilateral + IVC extension):</strong> For neonates with non‚Äìlife-threatening RVT, the ASH/ISTH guideline panel <strong><em>recommends</em></strong> anticoagulation alone vs thrombolysis followed by anticoagulation (<strong>strong recommendation</strong> based on very low certainty in the evidence of effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="rec-statement">
            <strong>Rec 10b ‚Äî Life-Threatening RVT (bilateral thrombosis):</strong> For neonates with life-threatening RVT, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using thrombolysis followed by anticoagulation, rather than anticoagulation alone (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">RVT Classification &amp; Treatment Decision</p>
              <table class="data-table">
                <thead><tr><th>Type of RVT</th><th>Definition</th><th>Treatment</th><th>Strength</th></tr></thead>
                <tbody>
                  <tr><td><strong>Non-life-threatening</strong></td><td>Unilateral, or unilateral + IVC extension</td><td>Anticoagulation alone ‚Äî NO thrombolysis</td><td>STRONG</td></tr>
                  <tr><td><strong>Life-threatening</strong></td><td>Bilateral thrombosis</td><td>Thrombolysis ‚Üí anticoagulation</td><td>Conditional</td></tr>
                </tbody>
              </table>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec10-applies')">Classification &amp; Rationale</button>
              <button class="panel-tab" onclick="switchTab(this,'rec10-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec10-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec10-applies" class="panel-content active">
              <p class="panel-heading">Classification &amp; Rationale</p>
              <p><strong>Non-life-threatening RVT (Rec 10a ‚Äî STRONG against thrombolysis):</strong></p>
              <ul>
                <li>Unilateral RVT</li>
                <li>Unilateral RVT with IVC extension</li>
                <li>Rationale: High value placed on avoiding thrombolysis bleeding risks, especially in neonates. High-quality evidence for HARM from thrombolysis; high costs; very low quality evidence for benefit.</li>
                <li><em>Note: A strong recommendation can be made even with very low certainty evidence when evidence for harm is of high quality</em></li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Life-threatening RVT (Rec 10b ‚Äî Conditional, thrombolysis):</strong></p>
              <ul>
                <li>Bilateral RVT (bilateral thrombosis)</li>
                <li>Rationale: When RVT is life-threatening, beneficial effects of thrombolysis may outweigh undesirable consequences</li>
                <li>Assess: gestational age, IVH, comorbidities, thrombocytopenia ‚Äî affect bleeding risk</li>
              </ul>
            </div>
            <div id="rec10-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm RVT diagnosis and laterality (unilateral vs bilateral)</li>
                <li>Assess IVC extension</li>
                <li>Assess gestational age, IVH, comorbidities, platelet count</li>
                <li><strong>Unilateral or unilateral + IVC (non-life-threatening):</strong> Use anticoagulation alone ‚Äî STRONG recommendation against thrombolysis</li>
                <li><strong>Bilateral (life-threatening):</strong> Consider thrombolysis followed by anticoagulation ‚Äî weigh bleeding risks carefully</li>
                <li>Long-term monitoring: blood pressure, renal function, kidney size</li>
                <li>Paediatric nephrology input recommended</li>
              </ol>
            </div>
            <div id="rec10-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Thrombolysis carries substantial bleeding risk in neonates ‚Äî particularly intracranial haemorrhage</li>
                <li>Evidence from observational studies where thrombolysis patients were critically ill ‚Äî causation difficult to assess</li>
                <li>Thrombolysis in neonates: avoid unless truly bilateral life-threatening disease</li>
                <li>Gestational age: premature neonates at much higher bleeding risk</li>
                <li>IVH: absolute relative contraindication to thrombolysis</li>
                <li>Thrombocytopenia: significant relative contraindication</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>Evidence derived from observational studies ‚Äî critically ill patients treated with thrombolysis, studies did not adjust for this bias</li>
                <li>Panel placed high value on avoiding bleeding risks of thrombolysis in neonates</li>
                <li>Strong recommendation 10a: high-quality evidence for harm + high costs despite very low quality evidence for benefit = basis for strong recommendation</li>
                <li>Certainty: very low for both 10a and 10b</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 11 (11a and 11b) -->
      <div class="rec-card cat-pvt" id="rec11">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 11a/b</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Portal Vein Thrombosis (PVT) ‚Äî Anticoagulation vs No Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For neonates and children with PVT, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            <strong>Rec 11a:</strong> For neonates and children with <strong>occlusive PVT</strong> and for children with <strong>non-occlusive PVT, post‚Äìliver transplant PVT, or unprovoked PVT</strong>, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation rather than no anticoagulation (conditional recommendation ‚äï‚óã‚óã‚óã).
          </div>
          <div class="rec-statement">
            <strong>Rec 11b:</strong> For neonates with <strong>nonocclusive PVT</strong>, and for children who have already developed <strong>portal hypertension (PHTN) secondary to PVT</strong>, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> no anticoagulation rather than using anticoagulation (conditional recommendation ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">PVT Treatment Summary</p>
              <table class="data-table">
                <thead><tr><th>Scenario</th><th>Recommendation</th></tr></thead>
                <tbody>
                  <tr><td>Neonates ‚Äî occlusive PVT</td><td>Anticoagulate (Rec 11a)</td></tr>
                  <tr><td>Children ‚Äî non-occlusive PVT</td><td>Anticoagulate (Rec 11a)</td></tr>
                  <tr><td>Children ‚Äî post‚Äìliver transplant PVT</td><td>Anticoagulate (Rec 11a)</td></tr>
                  <tr><td>Children ‚Äî unprovoked PVT</td><td>Anticoagulate (Rec 11a)</td></tr>
                  <tr><td>Neonates ‚Äî nonocclusive PVT</td><td>No anticoagulation (Rec 11b)</td></tr>
                  <tr><td>Children ‚Äî PHTN established secondary to PVT</td><td>No anticoagulation (Rec 11b)</td></tr>
                </tbody>
              </table>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec11-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec11-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec11-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec11-applies" class="panel-content active">
              <p class="panel-heading">Population</p>
              <p><strong>Rec 11a ‚Äî Anticoagulate:</strong></p>
              <ul>
                <li>Neonates with occlusive PVT</li>
                <li>Children with non-occlusive PVT</li>
                <li>Children with post‚Äìliver transplant PVT</li>
                <li>Children with unprovoked PVT</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Rec 11b ‚Äî No anticoagulation:</strong></p>
              <ul>
                <li>Neonates with nonocclusive PVT</li>
                <li>Children who have already developed PHTN secondary to PVT (risk of oesophageal variceal bleeding)</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div>Panel recognises increased risk of bleeding in paediatric patients with PHTN and oesophageal varices ‚Äî therefore does NOT recommend anticoagulation in established PHTN.</div>
              </div>
            </div>
            <div id="rec11-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm PVT diagnosis and characterise as occlusive or nonocclusive</li>
                <li>Assess for PHTN (portal hypertension) ‚Äî if established, recommend no anticoagulation</li>
                <li>Assess for liver transplant status</li>
                <li>In neonates: assess occlusive (treat) vs nonocclusive (do not treat)</li>
                <li>In children: treat if non-occlusive, post-transplant, or unprovoked</li>
                <li>If not treated: arrange close follow-up monitoring for extension or organ dysfunction</li>
                <li>If treated: select agent per Recs 17‚Äì20</li>
                <li>Paediatric hepatology/gastroenterology input recommended</li>
              </ol>
            </div>
            <div id="rec11-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>PHTN with oesophageal varices: significantly increased bleeding risk with anticoagulation ‚Äî do NOT anticoagulate (Rec 11b)</li>
                <li>Observational studies show PVT resolution in both treated and untreated patients ‚Äî benefit of anticoagulation uncertain</li>
                <li>Patients who did not receive anticoagulation: warrant follow-up monitoring ‚Äî extension or organ dysfunction may require reconsideration</li>
                <li>Evidence: very low certainty (observational studies only)</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>Evidence from observational studies only</li>
                <li>PVT resolution described in both anticoagulated and non-anticoagulated patients</li>
                <li>Panel valued avoiding long-term complications of persistent occlusive thrombus ‚Üí favoured treatment in most settings</li>
                <li>Panel recognised bleeding risk with PHTN/varices ‚Üí recommends against treatment in that setting</li>
                <li>Certainty: very low</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 12 (12a and 12b) -->
      <div class="rec-card cat-svt" id="rec12">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 12a/b</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Superficial Vein Thrombosis (SVT) ‚Äî Anticoagulation vs No Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with SVT, should anticoagulation vs no anticoagulation be used?</div>
          <div class="rec-statement">
            <strong>Rec 12a ‚Äî IV Cannula-Related Upper Limb SVT:</strong> For paediatric patients with SVT secondary to IV cannulation in the upper limb, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> no anticoagulation rather than using anticoagulation (conditional recommendation ‚äï‚óã‚óã‚óã).
          </div>
          <div class="rec-statement">
            <strong>Rec 12b ‚Äî Non-Cannula Upper Limb or Cancer/Varicose Vein-Related Lower Limb SVT:</strong> For paediatric patients with SVT in the upper limb which is not cannula related, or in the lower limbs associated with cancer or varicose veins, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> anticoagulation rather than no anticoagulation (conditional recommendation ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">SVT Decision Guide</p>
              <table class="data-table">
                <thead><tr><th>SVT Type</th><th>Recommendation</th></tr></thead>
                <tbody>
                  <tr><td>Upper limb ‚Äî IV cannula related (PIV, PICC)</td><td>No anticoagulation (Rec 12a)</td></tr>
                  <tr><td>Upper limb ‚Äî NOT cannula related</td><td>Anticoagulate (Rec 12b)</td></tr>
                  <tr><td>Lower limb ‚Äî cancer related</td><td>Anticoagulate (Rec 12b)</td></tr>
                  <tr><td>Lower limb ‚Äî varicose veins</td><td>Anticoagulate (Rec 12b)</td></tr>
                  <tr><td>Symptomatic SVT with progression</td><td>Consider anticoagulation</td></tr>
                </tbody>
              </table>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec12-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec12-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec12-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec12-applies" class="panel-content active">
              <p class="panel-heading">Population</p>
              <p><strong>Rec 12a (No anticoagulation):</strong></p>
              <ul>
                <li>SVT secondary to IV cannulation in the upper limb (PIV, PICC)</li>
                <li>Most peripheral IV/CVAD-related events in upper extremity</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Rec 12b (Anticoagulate):</strong></p>
              <ul>
                <li>SVT in upper limb ‚Äî NOT cannula related</li>
                <li>SVT in lower limbs associated with cancer</li>
                <li>SVT in lower limbs associated with varicose veins</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Consider anticoagulation for:</strong></p>
              <ul>
                <li>Symptomatic SVT (non-PIV/PICC-related)</li>
                <li>SVT with symptom progression</li>
                <li>Scenario: PIV/long-term PICC with progression</li>
              </ul>
              <div class="callout info">
                <span class="callout-icon">‚Ñπ</span>
                <div>When anticoagulation is prescribed for SVT, there is uncertainty about optimal intensity (prophylactic vs full dose) and duration of therapy.</div>
              </div>
            </div>
            <div id="rec12-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Confirm SVT diagnosis and characterise: location (upper/lower limb), aetiology (cannula vs non-cannula, cancer, varicose vein)</li>
                <li>Upper limb cannula-related: no anticoagulation; remove or replace cannula if no longer needed</li>
                <li>Upper limb non-cannula-related: anticoagulate ‚Äî select agent per Recs 17‚Äì20</li>
                <li>Lower limb cancer/varicose vein-related: anticoagulate</li>
                <li>Monitor for symptom progression ‚Äî reconsider anticoagulation if progression</li>
              </ol>
            </div>
            <div id="rec12-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>No direct and only limited indirect data available for this recommendation</li>
                <li>Panel experience-based recommendation for most cases</li>
                <li>Optimal intensity and duration of anticoagulation for SVT uncertain in paediatric patients</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>No direct and only limited indirect data upon which to base this recommendation</li>
                <li>Panel experience: most peripheral IV/CVAD-related upper extremity events do not require anticoagulation</li>
                <li>Certainty: very low</li>
              </ul>
            </div>
          </div>
        </div>
      </div>


      <!-- REC 13 -->
      <div class="rec-card cat-dvt-pe" id="rec13">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 13</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Proximal DVT ‚Äî Anticoagulation Alone vs Thrombolysis + Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with proximal DVT, should thrombolysis followed by anticoagulation vs anticoagulation alone be used?</div>
          <div class="rec-statement">
            For paediatric patients with proximal DVT, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation alone rather than thrombolysis followed by anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm proximal DVT</li>
                <li>Initiate anticoagulation alone as first-line (agent per Recs 17‚Äì20)</li>
                <li>Consider extent and clinical impact of VTE in risk-benefit assessment for thrombolysis</li>
                <li>Reserve thrombolysis for individuals where benefit clearly outweighs risk</li>
                <li>If thrombolysis considered: assess feasibility of catheter-directed vs systemic; refer to paediatric interventional radiology if available</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec13-remarks')">Remarks</button>
              <button class="panel-tab" onclick="switchTab(this,'rec13-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec13-remarks" class="panel-content active">
              <p class="panel-heading">Key Remarks</p>
              <ul>
                <li>In most cases, risks of thrombolysis seem higher than potential benefit for proximal DVT</li>
                <li>However, there may be individuals for whom the risk-benefit ratio favours thrombolysis (e.g., extensive thrombosis, threatened limb)</li>
                <li>Extrapolation from adult data was difficult for this recommendation</li>
                <li>Insufficient data to compare catheter-directed vs systemic thrombolysis in paediatric patients</li>
                <li>Centres with access to paediatric interventional radiology may have different perspectives ‚Äî local resources relevant</li>
                <li>Extent and clinical impact of VTE: important in determining risk-benefit ratio of thrombolysis</li>
              </ul>
            </div>
            <div id="rec13-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Thrombolysis carries substantial bleeding risk including intracranial haemorrhage</li>
                <li>No RCT data for thrombolysis in paediatric proximal DVT</li>
                <li>Risk-benefit assessment must consider: age, comorbidities, thrombus extent, access to paediatric IR</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 14 -->
      <div class="rec-card cat-pe-thrombolysis" id="rec14">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 14</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Submassive PE (RV Dysfunction, No Haemodynamic Compromise) ‚Äî Anticoagulation Alone vs Thrombolysis</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with submassive PE (right ventricular dysfunction without haemodynamic compromise), should thrombolysis followed by anticoagulation vs anticoagulation alone be used?</div>
          <div class="rec-statement">
            For paediatric patients with PE and echocardiographic or biochemical evidence of right ventricular dysfunction but without haemodynamic compromise, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using anticoagulation alone rather than thrombolysis followed by anticoagulation (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout warning">
            <span class="callout-icon">‚ö†</span>
            <div><strong>Adult data extrapolation:</strong> Minimal paediatric data available. Recent international adult guideline panels have recommended anticoagulation alone rather than thrombolysis for submassive PE (based on low certainty evidence).</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm submassive PE: RV dysfunction (echo or biomarkers) WITHOUT haemodynamic compromise</li>
                <li>Initiate anticoagulation alone ‚Äî do NOT routinely add thrombolysis</li>
                <li>Monitor closely for haemodynamic deterioration (progression to massive PE)</li>
                <li>If haemodynamic compromise develops ‚Üí escalate to thrombolysis (Rec 15)</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec14-definition')">Definition &amp; Criteria</button>
              <button class="panel-tab" onclick="switchTab(this,'rec14-cautions')">Harms &amp; Monitoring</button>
            </div>
            <div id="rec14-definition" class="panel-content active">
              <p class="panel-heading">Definition ‚Äî Submassive PE</p>
              <p>PE with <strong>both or either</strong> of:</p>
              <ul>
                <li><strong>Echocardiographic evidence</strong> of right ventricular dysfunction: right ventricular dilation OR intraventricular septal bowing to the left ventricle</li>
                <li><strong>Biochemical evidence</strong>: elevated troponin OR brain natriuretic peptide (BNP/NT-proBNP)</li>
              </ul>
              <p><strong>WITHOUT</strong> haemodynamic compromise (no systemic hypotension or signs of shock)</p>
              <div class="callout info">
                <span class="callout-icon">‚Ñπ</span>
                <div>Adult guidelines suggest thrombolysis may be reasonable to consider for younger patients with submassive PE at low risk of bleeding who have evidence of BOTH echocardiographic AND biochemical RV dysfunction. This may extrapolate to select paediatric patients ‚Äî use clinical judgement and specialist input.</div>
              </div>
            </div>
            <div id="rec14-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Monitoring</p>
              <ul>
                <li>Monitor submassive PE closely for development of haemodynamic compromise ‚Äî if it occurs, escalate to thrombolysis (Rec 15)</li>
                <li>Thrombolysis risks outweigh benefits in most submassive PE cases without haemodynamic compromise</li>
                <li>Consider intensive monitoring (PICU setting) for submassive PE</li>
                <li>No paediatric RCT data ‚Äî recommendation based on adult guidelines + clinical reasoning</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 15 -->
      <div class="rec-card cat-pe-thrombolysis" id="rec15">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 15</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Massive PE (With Haemodynamic Compromise) ‚Äî Thrombolysis + Anticoagulation</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with massive PE (with haemodynamic compromise), should thrombolysis followed by anticoagulation vs anticoagulation alone be used?</div>
          <div class="rec-statement">
            For paediatric patients with PE and haemodynamic compromise the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using thrombolysis followed by anticoagulation rather than anticoagulation alone (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout warning">
            <span class="callout-icon">‚ö†</span>
            <div><strong>Adult data extrapolation + limited paediatric data:</strong> This recommendation is based predominantly on extrapolation from recent adult guidelines AND 3 small paediatric studies suggesting a trend toward decreased mortality with thrombolysis in massive PE.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Quick Action Steps</p>
              <ol style="list-style:decimal; padding-left:1.5rem; font-size:0.82rem; line-height:1.6;">
                <li>Confirm massive PE: haemodynamic compromise (systemic hypotension, signs of shock)</li>
                <li>Immediate thrombolysis followed by anticoagulation ‚Äî life-threatening emergency</li>
                <li>Involve paediatric intensivist and haematologist urgently</li>
                <li>Consider local thrombolytic agent availability and protocol</li>
                <li>Post-thrombolysis: initiate anticoagulation per Recs 17‚Äì20</li>
              </ol>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec15-definition')">Definition &amp; Criteria</button>
              <button class="panel-tab" onclick="switchTab(this,'rec15-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec15-definition" class="panel-content active">
              <p class="panel-heading">Definition ‚Äî Massive PE</p>
              <p>PE with <strong>haemodynamic compromise</strong> that may be life threatening, with <strong>limited time to respond to standard anticoagulation</strong></p>
              <ul>
                <li>Systemic hypotension</li>
                <li>Signs of shock (altered consciousness, cold extremities, reduced urine output)</li>
                <li>Life-threatening situation ‚Äî requires immediate intervention</li>
              </ul>
            </div>
            <div id="rec15-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Thrombolysis carries substantial bleeding risk ‚Äî including fatal intracranial haemorrhage</li>
                <li>Risk-benefit: in haemodynamically compromised massive PE, benefit likely outweighs risk</li>
                <li>3 small paediatric studies suggest trend toward decreased mortality (not definitive evidence)</li>
                <li>Assess for contraindications to thrombolysis before administering</li>
                <li>Post-thrombolysis: delay initiation of full-dose anticoagulation until bleeding risk acceptable</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 16 -->
      <div class="rec-card cat-cvad" id="rec16">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 16</div>
          <div class="rec-title-block">
            <div class="rec-short-title">CVAD Removal ‚Äî Immediate vs Delayed Removal (Symptomatic CVAD Thrombosis, No Longer Required or Nonfunctioning)</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-l">‚äï‚äï‚óã‚óã LOW</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with symptomatic CVAD-related thrombosis who no longer require venous access or whose CVAD is nonfunctioning, should immediate or delayed removal of the CVAD be used?</div>
          <div class="rec-statement">
            For paediatric patients with symptomatic CVAD-related thrombosis who no longer require venous access or whose CVAD is nonfunctioning, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> either immediate removal or delayed removal of the CVAD (conditional recommendation based on <strong>low certainty</strong> in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚äï‚óã‚óã).
          </div>
          <div class="callout info">
            <span class="callout-icon">‚Ñπ</span>
            <div>This recommendation has <strong>LOW certainty</strong> (‚äï‚äï‚óã‚óã) ‚Äî slightly higher than the very low certainty of most other recommendations in this guideline.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">CVAD Management Summary</p>
              <table class="data-table">
                <thead><tr><th>Clinical Scenario</th><th>2024 Recommendation</th><th>Basis</th></tr></thead>
                <tbody>
                  <tr><td>CVAD no longer required OR nonfunctioning</td><td>Either immediate OR delayed (‚â•48h anticoagulation) removal</td><td>Rec 16 (2024) ‚Äî ‚äï‚äï‚óã‚óã</td></tr>
                  <tr><td>CVAD still required + functioning (2018 Rec 9)</td><td>No removal ‚Äî continue anticoagulation with CVAD in situ</td><td>2018 guideline ‚Äî conditional</td></tr>
                  <tr><td>CVAD nonfunctioning or unneeded (2018 Rec 10)</td><td>REMOVE ‚Äî strong recommendation</td><td>2018 guideline ‚Äî STRONG</td></tr>
                  <tr><td>Large clot burden or right-to-left shunt</td><td>Anticoagulate a few days before removal</td><td>Rec 16 remarks</td></tr>
                </tbody>
              </table>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec16-applies')">Who it Applies To</button>
              <button class="panel-tab" onclick="switchTab(this,'rec16-action')">Action Steps</button>
              <button class="panel-tab" onclick="switchTab(this,'rec16-cautions')">Harms &amp; Cautions</button>
            </div>
            <div id="rec16-applies" class="panel-content active">
              <p class="panel-heading">Population &amp; Context</p>
              <p><strong>Applies to:</strong> Paediatric patients with symptomatic CVAD-related thrombosis who:</p>
              <ul>
                <li>No longer require venous access, OR</li>
                <li>CVAD is nonfunctioning</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Delayed removal preferred for:</strong></p>
              <ul>
                <li>Large thrombotic burden</li>
                <li>Right-to-left cardiac shunts (risk of paradoxical embolism)</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>2018 Rec 9 (unchanged):</strong> CVAD still required and functioning ‚Üí NO removal; continue anticoagulation with CVAD in situ</p>
              <p><strong>2018 Rec 10 (unchanged):</strong> CVAD nonfunctioning or unneeded ‚Üí STRONG recommendation for removal</p>
            </div>
            <div id="rec16-action" class="panel-content">
              <p class="panel-heading">Action Steps</p>
              <ol style="font-size:0.82rem; line-height:1.6; list-style:decimal; padding-left:1.5rem;">
                <li>Assess: does patient still require venous access? Is CVAD functioning?</li>
                <li>If still required + functioning: keep CVAD in situ; continue anticoagulation (2018 Rec 9)</li>
                <li>If no longer required OR nonfunctioning: plan removal</li>
                <li>Assess for large thrombotic burden or right-to-left cardiac shunt</li>
                <li>If large burden or right-to-left shunt: anticoagulate for a few days before removal to reduce embolisation risk</li>
                <li>If no high-risk features: immediate removal is acceptable</li>
                <li>Document rationale for timing of removal</li>
              </ol>
            </div>
            <div id="rec16-cautions" class="panel-content">
              <p class="panel-heading">Harms &amp; Cautions</p>
              <ul>
                <li>Recent observational studies: &gt;48 hours anticoagulation before CVAD removal vs immediate removal were comparable for risk of PE or paradoxical stroke</li>
                <li>Large thrombotic burden: may benefit from anticoagulation prior to removal to reduce embolisation risk</li>
                <li>Right-to-left cardiac shunts: risk of paradoxical embolism on removal</li>
                <li>Certainty: low (‚äï‚äï‚óã‚óã) ‚Äî highest certainty of any recommendation in this guideline</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li>Recent observational studies provided data: &gt;48 hours anticoagulation before removal vs immediate removal ‚Äî comparable risk of emboli leading to PE or paradoxical stroke</li>
                <li>Certainty: LOW (‚äï‚äï‚óã‚óã) ‚Äî slightly higher than most recommendations</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 17 -->
      <div class="rec-card cat-doac" id="rec17">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 17</div>
          <div class="rec-title-block">
            <div class="rec-short-title">DOACs (Rivaroxaban/Dabigatran) vs SOC Anticoagulants</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with VTE, should DOACs vs SOC anticoagulants be used?</div>
          <div class="rec-statement">
            For paediatric patients with VTE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using DOACs (rivaroxaban/dabigatran) over SOC anticoagulants (LMWH, UFH, VKAs, and fondaparinux; conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout success">
            <span class="callout-icon">‚úì</span>
            <div>DOACs are now the <strong>preferred first-line agents</strong> over SOC (LMWH/UFH/VKA/fondaparinux) for most paediatric patients with VTE in these updated guidelines.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">DOAC vs SOC ‚Äî Key Summary</p>
              <ul style="font-size:0.82rem; line-height:1.6;">
                <li><strong>Favours DOACs:</strong> Reduced thrombus recurrence; improved thrombus resolution; reduction in major bleeding vs LMWH/UFH; oral ‚Äî no injections; no routine monitoring; better QOL</li>
                <li><strong>Concerns:</strong> Increase in CRNMB; heavier menstrual bleeding (rivaroxaban); GI side effects (dabigatran); limited data for age &lt;6 months (rivaroxaban) and &lt;2 years low body weight (dabigatran)</li>
                <li><strong>NOT included:</strong> Apixaban and edoxaban ‚Äî phase 3 paediatric trial data not yet published</li>
              </ul>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec17-exclusions')">Important Exclusions</button>
              <button class="panel-tab" onclick="switchTab(this,'rec17-comparison')">Benefits vs Harms</button>
              <button class="panel-tab" onclick="switchTab(this,'rec17-monitoring')">Monitoring</button>
            </div>
            <div id="rec17-exclusions" class="panel-content active">
              <p class="panel-heading">Important Exclusions ‚Äî Where DOAC Evidence Does NOT Apply</p>
              <p><strong>Rivaroxaban (EINSTEIN-Junior) excluded:</strong></p>
              <ul>
                <li>Age &lt;6 months</li>
                <li>Low birth weight</li>
                <li>Severe liver impairment</li>
                <li>Severe renal impairment</li>
              </ul>
              <p style="margin-top:0.5rem;"><strong>Dabigatran (DIVERSITY) excluded:</strong></p>
              <ul>
                <li>Age &lt;2 years with low body weight</li>
                <li>Severe liver impairment</li>
                <li>Severe renal impairment</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div>Use of DOACs in excluded populations is NOT supported by trial evidence. Use SOC (LMWH/UFH) for these patients.</div>
              </div>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div><strong>Apixaban and edoxaban:</strong> NOT considered in these guidelines ‚Äî phase 3 paediatric trial data not yet published at time of guideline development.</div>
              </div>
            </div>
            <div id="rec17-comparison" class="panel-content">
              <p class="panel-heading">Benefits vs Harms of DOACs vs SOC</p>
              <table class="data-table">
                <thead><tr><th>Outcome</th><th>DOACs vs SOC</th></tr></thead>
                <tbody>
                  <tr><td>Thrombus recurrence</td><td>Small reduction with DOACs</td></tr>
                  <tr><td>Thrombus resolution</td><td>Improved with DOACs</td></tr>
                  <tr><td>Major bleeding</td><td>Reduced with DOACs</td></tr>
                  <tr><td>CRNMB</td><td>Increased with DOACs</td></tr>
                  <tr><td>Mortality</td><td>Uncertain (small event numbers)</td></tr>
                  <tr><td>PTS</td><td>Uncertain (insufficient follow-up)</td></tr>
                  <tr><td>QOL</td><td>Better with DOACs (oral, no monitoring)</td></tr>
                  <tr><td>Menstrual bleeding (rivaroxaban)</td><td>Heavier menstrual bleeding reported</td></tr>
                  <tr><td>GI side effects (dabigatran)</td><td>Increased GI side effects</td></tr>
                </tbody>
              </table>
              <p style="font-size:0.76rem; margin-top:0.5rem; color:#666;">*Note: Evaluation at 3‚Äì6 months considered too soon for accurate PTS and recurrence data. Panel acknowledged limitations of small event numbers.</p>
            </div>
            <div id="rec17-monitoring" class="panel-content">
              <p class="panel-heading">Monitoring</p>
              <ul>
                <li><strong>Rivaroxaban:</strong> No routine monitoring required per current approvals</li>
                <li><strong>Dabigatran:</strong> Monitoring and dose adjustment required per DIVERSITY trial protocol; current approvals do NOT require monitoring ‚Äî panel concern about efficacy/safety of routine use per current approvals</li>
                <li><strong>LMWH:</strong> Anti-Xa levels; weight-based dosing</li>
                <li><strong>UFH:</strong> Standard monitoring protocols</li>
                <li><strong>VKA:</strong> INR monitoring</li>
              </ul>
            </div>
            <div class="evidence-panel">
              <hr style="margin:0.75rem 0;">
              <p class="panel-heading">Evidence Summary</p>
              <ul>
                <li><strong>EINSTEIN-Junior</strong> (n=500): rivaroxaban vs SOC (LMWH or VKA) ‚Äî small benefit in reduced recurrence and improved resolution; reduced major bleeding; increased CRNMB; heavier menstrual bleeding</li>
                <li><strong>DIVERSITY</strong> (n=267): dabigatran vs SOC ‚Äî small benefit; fewer major bleeds; equivalent CRNMB; GI side effects; monitoring/dose adjustment in trial raised concern for routine use</li>
                <li>Panel acknowledged limitations: small event numbers, evaluation at 3‚Äì6 months</li>
                <li>QOL, cost-effectiveness, acceptability of oral agent without monitoring: important factors</li>
                <li>Certainty: very low</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 18 -->
      <div class="rec-card cat-doac" id="rec18">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 18</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Rivaroxaban vs SOC Anticoagulants (EINSTEIN-Junior)</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with VTE, should rivaroxaban vs SOC anticoagulants be used?</div>
          <div class="rec-statement">
            For paediatric patients with VTE the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using rivaroxaban over SOC anticoagulants (LMWH, UFH, VKA, and fondaparinux; conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Rivaroxaban Key Points</p>
              <ul style="font-size:0.82rem; line-height:1.6;">
                <li>Key trial: EINSTEIN-Junior (n=500; age &gt;37wk GA to 17y)</li>
                <li>Benefits: reduced thrombus recurrence; improved resolution; reduced major bleeding</li>
                <li>Harms: increased CRNMB; heavier menstrual bleeding in adolescent females</li>
                <li>Excluded: age &lt;6 months; low birth weight; severe liver/renal impairment</li>
                <li>No routine monitoring required</li>
              </ul>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec18-trial')">EINSTEIN-Junior Trial</button>
              <button class="panel-tab" onclick="switchTab(this,'rec18-cautions')">Exclusions &amp; Cautions</button>
            </div>
            <div id="rec18-trial" class="panel-content active">
              <p class="panel-heading">EINSTEIN-Junior Key Data</p>
              <ul>
                <li><strong>Design:</strong> Randomised; rivaroxaban vs LMWH or VKA (SOC)</li>
                <li><strong>Population:</strong> n=500; birth &gt;37wk GA to age 17 years</li>
                <li><strong>Benefits:</strong> Small benefit in reduced thrombus recurrence rate; increased rate of thrombus resolution</li>
                <li><strong>Major bleeding:</strong> Reduced with rivaroxaban vs SOC</li>
                <li><strong>CRNMB:</strong> Increased with rivaroxaban</li>
                <li><strong>Menstrual bleeding:</strong> Heavier menstrual bleeding reported in adolescent females</li>
                <li><strong>Limitation:</strong> Small number of outcome events; 3‚Äì6 month evaluation may underestimate PTS</li>
              </ul>
            </div>
            <div id="rec18-cautions" class="panel-content">
              <p class="panel-heading">Exclusions &amp; Cautions</p>
              <ul>
                <li>Age &lt;6 months: excluded ‚Äî do NOT use rivaroxaban (insufficient evidence)</li>
                <li>Low birth weight: excluded ‚Äî insufficient evidence</li>
                <li>Severe liver impairment: excluded ‚Äî avoid rivaroxaban</li>
                <li>Severe renal impairment: excluded ‚Äî avoid rivaroxaban</li>
                <li>Adolescent females: counsel regarding increased menstrual bleeding</li>
                <li>No routine drug level monitoring required</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 19 -->
      <div class="rec-card cat-doac" id="rec19">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 19</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Dabigatran vs SOC Anticoagulants (DIVERSITY)</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with VTE, should dabigatran vs SOC anticoagulants be used?</div>
          <div class="rec-statement">
            For paediatric patients with VTE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using dabigatran over SOC anticoagulants (LMWH, UFH, VKA, and fondaparinux; conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout warning">
            <span class="callout-icon">‚ö†</span>
            <div><strong>Important monitoring concern:</strong> Monitoring and dose adjustment of dabigatran was required during the DIVERSITY trial. Current approvals do NOT require such monitoring. The panel raised concern about the potential effect on efficacy and safety of routine use per current approvals.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Dabigatran Key Points</p>
              <ul style="font-size:0.82rem; line-height:1.6;">
                <li>Key trial: DIVERSITY (n=267; age &gt;37wk GA to &lt;18y)</li>
                <li>Benefits: reduced thrombus recurrence; improved resolution; fewer major bleeds</li>
                <li>Harms: equivalent CRNMB; gastrointestinal side effects</li>
                <li>Excluded: age &lt;2 years with low body weight; severe liver/renal impairment</li>
                <li>Monitoring concern: required in trial but not in current approvals</li>
              </ul>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec19-trial')">DIVERSITY Trial</button>
              <button class="panel-tab" onclick="switchTab(this,'rec19-cautions')">Exclusions &amp; Cautions</button>
            </div>
            <div id="rec19-trial" class="panel-content active">
              <p class="panel-heading">DIVERSITY Key Data</p>
              <ul>
                <li><strong>Design:</strong> Randomised; dabigatran vs SOC</li>
                <li><strong>Population:</strong> n=267; birth &gt;37wk GA to age &lt;18 years</li>
                <li><strong>Benefits:</strong> Small benefit in reduced thrombus recurrence; improved thrombus resolution</li>
                <li><strong>Major bleeding:</strong> Fewer major bleeds with dabigatran</li>
                <li><strong>CRNMB:</strong> Equivalent to SOC</li>
                <li><strong>GI side effects:</strong> Increased with dabigatran</li>
                <li><strong>Monitoring concern:</strong> Monitoring and dose adjustment required during trial; current approvals do not require ‚Äî potential concern re efficacy/safety</li>
              </ul>
            </div>
            <div id="rec19-cautions" class="panel-content">
              <p class="panel-heading">Exclusions &amp; Cautions</p>
              <ul>
                <li>Age &lt;2 years with low body weight: excluded ‚Äî insufficient evidence for dabigatran</li>
                <li>Severe liver impairment: excluded ‚Äî avoid</li>
                <li>Severe renal impairment: excluded ‚Äî avoid</li>
                <li>GI side effects: counsel patients; may affect adherence</li>
                <li>Dabigatran capsules: contents can be sprinkled on food for younger children ‚Äî check local guidance</li>
                <li>Consider jurisdictional availability and regulatory approval status</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

      <!-- REC 20 -->
      <div class="rec-card cat-doac" id="rec20">
        <div class="rec-card-header" onclick="toggleCard(this)" aria-expanded="false">
          <div class="rec-number">Rec 20</div>
          <div class="rec-title-block">
            <div class="rec-short-title">Rivaroxaban vs Dabigatran ‚Äî No Preference; Agent Selection Factors</div>
            <div class="rec-badges">
              <span class="badge badge-conditional">Conditional</span>
              <span class="badge badge-certainty-vl">‚äï‚óã‚óã‚óã Very Low</span>
            </div>
          </div>
          <span class="rec-chevron" aria-hidden="true">‚ñº</span>
        </div>
        <div class="rec-card-body">
          <div class="pico-q"><span class="pico-label">PICO Question</span>For paediatric patients with VTE, should either rivaroxaban or dabigatran be preferentially used?</div>
          <div class="rec-statement">
            For paediatric patients with VTE, the ASH/ISTH guideline panel <strong><em>suggests</em></strong> using either rivaroxaban or dabigatran, although there may be individual populations or jurisdictional availability that would lead clinicians to choose 1 agent over the other (conditional recommendation based on very low certainty in the evidence about effects <span class="grade-display"><span class="grade-dot filled"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span><span class="grade-dot empty"></span></span> ‚äï‚óã‚óã‚óã).
          </div>
          <div class="callout info">
            <span class="callout-icon">‚Ñπ</span>
            <div>The panel was <strong>unable to distinguish one DOAC as preferred over the other</strong> after a formal review of the evidence-to-decisions (EtDs) for rivaroxaban vs SOC and dabigatran vs SOC.</div>
          </div>
          <div class="card-panels">
            <div class="quick-content">
              <p class="panel-heading">Factors That May Favour One Agent Over the Other</p>
              <table class="data-table">
                <thead><tr><th>Factor</th><th>Consideration</th></tr></thead>
                <tbody>
                  <tr><td>Age &lt;6 months</td><td>Neither rivaroxaban nor dabigatran ‚Äî use SOC (LMWH/UFH)</td></tr>
                  <tr><td>Age &lt;2 years, low body weight</td><td>Dabigatran not supported ‚Äî prefer rivaroxaban if age ‚â•6m, or SOC</td></tr>
                  <tr><td>Adolescent females</td><td>Rivaroxaban: heavier menstrual bleeding ‚Äî consider dabigatran</td></tr>
                  <tr><td>GI tolerance</td><td>Dabigatran: more GI side effects ‚Äî consider rivaroxaban</td></tr>
                  <tr><td>Liver/renal impairment</td><td>Both excluded from trials ‚Äî use SOC</td></tr>
                  <tr><td>Local availability</td><td>Check jurisdictional approval and formulary access</td></tr>
                  <tr><td>Drug monitoring concern</td><td>Dabigatran: monitoring required in trial; rivaroxaban: no monitoring</td></tr>
                </tbody>
              </table>
              <div class="callout warning" style="margin-top:0.75rem;">
                <span class="callout-icon">‚ö†</span>
                <div><strong>Apixaban and edoxaban are NOT included in these guidelines</strong> ‚Äî phase 3 paediatric trial data were not yet published at the time of guideline development.</div>
              </div>
            </div>
            <div class="panel-tabs">
              <button class="panel-tab active" onclick="switchTab(this,'rec20-factors')">Selection Factors</button>
              <button class="panel-tab" onclick="switchTab(this,'rec20-remarks')">Panel Methodology</button>
            </div>
            <div id="rec20-factors" class="panel-content active">
              <p class="panel-heading">Agent Selection Factors</p>
              <ul>
                <li>Local/jurisdictional availability and approval status</li>
                <li>Patient age and weight (exclusion criteria of each trial)</li>
                <li>GI tolerability (dabigatran: GI side effects; rivaroxaban: menstrual bleeding)</li>
                <li>Need for monitoring (dabigatran dosing adjustment in trial raises concern; neither required per current approvals)</li>
                <li>Liver/renal function</li>
                <li>Patient/family preference (oral formulation, palatability)</li>
              </ul>
              <div class="callout warning">
                <span class="callout-icon">‚ö†</span>
                <div>Apixaban and edoxaban: NOT considered in these guidelines ‚Äî phase 3 paediatric trial data yet to be published.</div>
              </div>
            </div>
            <div id="rec20-remarks" class="panel-content">
              <p class="panel-heading">Panel EtD Methodology</p>
              <ul>
                <li>Panel undertook a formal evidence-to-decisions (EtD) review comparing rivaroxaban vs SOC and dabigatran vs SOC</li>
                <li><strong>Highest weighting:</strong> Balance of effects; certainty in the evidence; acceptability and feasibility of implementation</li>
                <li><strong>Moderate weighting:</strong> Resources required</li>
                <li><strong>Lowest weighting:</strong> Cost-effectiveness; equity</li>
                <li>After applying these weights: panel could not distinguish one agent as preferred over the other</li>
              </ul>
            </div>
          </div>
        </div>
      </div>

    </section><!-- end recommendations -->


    <!-- DRUG IMPLEMENTATION SECTION -->
    <div id="no-results" style="display:none; text-align:center; padding:3rem 1rem; color:var(--clr-text-muted); font-size:0.9rem; font-weight:500;">No recommendations match your search. Try a different term.</div>

    <section id="drug-implementation" class="page-section">
      <h2 class="section-title"><span class="section-icon">üíä</span> Drug Implementation Guidance</h2>

      <div class="drug-card">
        <h3>First-Line Preferred: DOACs (Rivaroxaban or Dabigatran)</h3>
        <p style="font-size:0.82rem; margin-bottom:0.5rem;">As per Recommendations 17‚Äì20: DOACs preferred over SOC for most paediatric patients with VTE.</p>
        <ul>
          <li><strong>Advantages:</strong> Oral; no routine monitoring required; better QOL; reduced major bleeding vs LMWH/UFH; small reduction in recurrence and improvement in resolution</li>
          <li><strong>Disadvantages:</strong> Increase in CRNMB; heavier menstrual bleeding (rivaroxaban); GI side effects (dabigatran); monitoring concern for dabigatran per trial protocol</li>
          <li><strong>Evidence base:</strong> EINSTEIN-Junior (rivaroxaban, n=500) and DIVERSITY (dabigatran, n=267)</li>
        </ul>
      </div>

      <div class="drug-card" style="border-left-color: var(--clr-accent2);">
        <h3>SOC Agents: LMWH / UFH / VKA / Fondaparinux</h3>
        <p style="font-size:0.82rem; margin-bottom:0.5rem;">Still appropriate and may be preferred in the following situations:</p>
        <ul>
          <li>Age &lt;6 months (rivaroxaban excluded) or &lt;2 years with low body weight (dabigatran excluded)</li>
          <li>Severe liver impairment</li>
          <li>Severe renal impairment</li>
          <li>High bleeding risk scenarios: CSVT with haemorrhage; post-invasive procedures ‚Üí use short half-life agent (UFH) for rapid reversal (GPS 2)</li>
          <li>Resource-limited settings where DOAC access/cost is a barrier</li>
        </ul>
      </div>

      <div class="drug-card" style="border-left-color: var(--clr-accent);">
        <h3>Short Half-Life Agent (UFH) ‚Äî High Bleeding Risk Situations</h3>
        <p style="font-size:0.82rem; margin-bottom:0.5rem;"><strong>Good Practice Statement 2 (GPS 2):</strong> Consider UFH rather than LMWH or DOACs in high bleeding risk patients:</p>
        <ul>
          <li>CSVT with haemorrhage secondary to venous congestion</li>
          <li>Immediately after or anticipated invasive procedures</li>
          <li>To decrease risk of worsening haemorrhage or bleeds</li>
          <li>Allows rapid reversal via discontinuation ¬± protamine</li>
        </ul>
      </div>

      <div class="callout warning">
        <span class="callout-icon">‚ö†</span>
        <div><strong>Apixaban and edoxaban are NOT included in these guidelines.</strong> Phase 3 paediatric trial data had not been published at the time of guideline development. Do not extrapolate adult data for apixaban/edoxaban use in paediatric patients without paediatric-specific evidence.</div>
      </div>

      <h3 style="font-size:0.9rem; font-weight:700; color:var(--clr-primary); margin:1.25rem 0 0.5rem;">Monitoring Principles</h3>
      <table class="age-table">
        <thead>
          <tr><th>Agent</th><th>Monitoring Required</th><th>Notes</th></tr>
        </thead>
        <tbody>
          <tr><td><strong>Rivaroxaban</strong></td><td>None required (per current approvals)</td><td>No routine monitoring; weight-based dosing</td></tr>
          <tr><td><strong>Dabigatran</strong></td><td>None required (per current approvals)</td><td>Concern: monitoring and dose adjustment was required in DIVERSITY trial; not per current approvals ‚Äî panel concern re efficacy/safety</td></tr>
          <tr><td><strong>LMWH</strong></td><td>Anti-Xa levels</td><td>Weight-based dosing; dose adjust to target anti-Xa range</td></tr>
          <tr><td><strong>UFH</strong></td><td>Per standard protocols (APTT or anti-Xa)</td><td>IV infusion; adjust per protocol; short half-life for high-risk situations</td></tr>
          <tr><td><strong>VKA</strong></td><td>INR monitoring</td><td>Multiple drug interactions; dietary vitamin K consistency required</td></tr>
          <tr><td><strong>Fondaparinux</strong></td><td>Anti-Xa (in selected cases)</td><td>SOC; limited paediatric data</td></tr>
        </tbody>
      </table>

      <div class="callout info" style="margin-top:1rem;">
        <span class="callout-icon">‚Ñπ</span>
        <div><strong>Numeric dosing tables are NOT included in this summary.</strong> Dosing information was not provided in the guideline text summarised here. Refer to: (1) the original publication supplementary data; (2) individual drug Summary of Product Characteristics (SPCs); (3) local formularies and pharmacy guidance; (4) BNFc (British National Formulary for Children) or equivalent local resources.</div>
      </div>

      <h3 style="font-size:0.9rem; font-weight:700; color:var(--clr-primary); margin:1.25rem 0 0.5rem;">CVAD Removal ‚Äî Timing Guidance (Rec 16)</h3>
      <table class="age-table">
        <thead>
          <tr><th>Clinical Scenario</th><th>Action</th><th>Source</th></tr>
        </thead>
        <tbody>
          <tr><td>CVAD no longer required OR nonfunctioning</td><td>Either immediate OR delayed removal (‚â•48h anticoagulation before removal)</td><td>Rec 16 (2024) ‚Äî ‚äï‚äï‚óã‚óã</td></tr>
          <tr><td>CVAD still required AND functioning</td><td>No removal ‚Äî continue anticoagulation with CVAD in situ</td><td>2018 Rec 9 ‚Äî conditional</td></tr>
          <tr><td>CVAD nonfunctioning or unneeded</td><td>REMOVE (strong recommendation)</td><td>2018 Rec 10 ‚Äî STRONG</td></tr>
          <tr><td>Large thrombotic burden or right-to-left shunt</td><td>Anticoagulate for a few days before removal</td><td>Rec 16 remarks</td></tr>
          <tr><td>Worsening signs/symptoms despite anticoagulation + CVAD still required</td><td>Either removal or no removal (individualise)</td><td>2018 Rec 12 ‚Äî conditional</td></tr>
        </tbody>
      </table>
    </section>

    <!-- SPECIAL SITUATIONS SECTION -->
    <section id="special-situations" class="page-section">
      <h2 class="section-title"><span class="section-icon">‚ö°</span> Special Situations</h2>
      <p style="font-size:0.82rem; color:#555; margin-bottom:1rem;">Click each situation to expand detailed guidance.</p>

      <!-- Situation 1: CSVT with Haemorrhage -->
      <div class="situation-card" id="sit1">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>1. CSVT with Haemorrhage ‚Äî Critical Decision Points</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <div class="callout danger">
            <span class="callout-icon">üö®</span>
            <div><strong>Do NOT withhold anticoagulation</strong> for haemorrhage that is secondary to venous congestion from CSVT. Anticoagulation is recommended in this scenario.</div>
          </div>
          <table class="data-table" style="margin-top:0.75rem;">
            <thead><tr><th>Haemorrhage Type</th><th>Action</th></tr></thead>
            <tbody>
              <tr><td>Haemorrhage DUE TO venous congestion (thrombus obstruction)</td><td>ANTICOAGULATE ‚Äî Rec 5</td></tr>
              <tr><td>Haemorrhage from other aetiology</td><td>Individualise carefully</td></tr>
              <tr><td>Intracranial haemorrhage unrelated to CSVT</td><td>Do NOT automatically anticoagulate</td></tr>
              <tr><td>Premature neonates with IVH</td><td>Higher bleeding risk ‚Äî individual assessment; consider UFH (GPS 2)</td></tr>
            </tbody>
          </table>
          <ul style="margin-top:0.75rem; font-size:0.82rem; line-height:1.5;">
            <li>Infection-associated CSVT: also treat underlying infection (surgical intervention if needed)</li>
            <li>High bleeding risk: prefer short half-life agent UFH (GPS 2)</li>
            <li>Neurologic deterioration despite anticoagulation ‚Üí consider thrombolysis/reperfusion (Rec 6)</li>
            <li>Cavernous sinus thrombosis: anticoagulate if no contraindications (pathophysiology may differ)</li>
          </ul>
        </div>
      </div>

      <!-- Situation 2: Submassive vs Massive PE -->
      <div class="situation-card" id="sit2">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>2. Submassive vs Massive PE ‚Äî Classification and Treatment</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <table class="data-table">
            <thead><tr><th>PE Type</th><th>Definition</th><th>Treatment (Rec)</th><th>Monitoring</th></tr></thead>
            <tbody>
              <tr>
                <td><strong>Submassive PE</strong></td>
                <td>RV dysfunction (echo: RV dilation, septal bowing; OR biochemical: elevated troponin/BNP) WITHOUT haemodynamic compromise</td>
                <td>Anticoagulation ALONE (Rec 14) ‚Äî conditional</td>
                <td>Close monitoring for haemodynamic deterioration</td>
              </tr>
              <tr>
                <td><strong>Massive PE</strong></td>
                <td>Haemodynamic compromise ‚Äî systemic hypotension or signs of shock; life-threatening; limited time to respond to anticoagulation</td>
                <td>Thrombolysis ‚Üí anticoagulation (Rec 15) ‚Äî conditional</td>
                <td>PICU; urgent intervention</td>
              </tr>
            </tbody>
          </table>
          <div class="callout warning" style="margin-top:0.75rem;">
            <span class="callout-icon">‚ö†</span>
            <div>Submassive PE: monitor closely for progression to haemodynamic compromise ‚Äî if it occurs, escalate to thrombolysis per Rec 15. Adult guidelines may suggest considering thrombolysis for younger patients with submassive PE who have both echocardiographic AND biochemical RV dysfunction at low bleeding risk.</div>
          </div>
          <div class="callout warning">
            <span class="callout-icon">‚ö†</span>
            <div>Rec 15 is based predominantly on adult guideline extrapolation plus 3 small paediatric studies suggesting trend toward decreased mortality. Direct paediatric RCT evidence is absent.</div>
          </div>
        </div>
      </div>

      <!-- Situation 3: RAT Risk Stratification -->
      <div class="situation-card" id="sit3">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>3. Right Atrial Thrombosis (RAT) ‚Äî Risk Stratification Algorithm</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <p style="font-size:0.82rem; font-weight:700; color:var(--clr-accent2); margin-bottom:0.5rem;">High-Risk Features (any = consider anticoagulation if bleeding risk acceptable):</p>
          <ol style="font-size:0.82rem; line-height:1.6;">
            <li>Large size (&gt;2 cm in any dimension or &gt;50% of right atrium)</li>
            <li>Snake-shaped or pedunculated morphology</li>
            <li>Mobile thrombus</li>
            <li>Location involving tricuspid valve or restricting blood flow through it</li>
            <li>Intracardiac right-to-left shunt or patent foramen ovale</li>
            <li>Associated CVAD (and location of thrombus relative to catheter)</li>
            <li>Symptoms: arrhythmias, haemodynamic compromise, emboli</li>
            <li>Increasing size despite therapeutic anticoagulation</li>
            <li>Concomitant cardiac anomalies: decreased function, abnormal rhythm, pacemaker/ICD</li>
          </ol>
          <div style="margin-top:0.75rem; padding:0.75rem; background:#f0faf4; border-radius:var(--radius); border:1px solid #a8ddb8; font-size:0.82rem;">
            <strong style="color:var(--clr-success);">If NO high-risk features are present:</strong>
            <ul style="margin-top:0.25rem;">
              <li>No anticoagulation (Rec 7b)</li>
              <li>Close radiological reassessment within 3 days</li>
              <li>Withholding anticoagulation is appropriate for small, mural, asymptomatic thrombi</li>
              <li>Wait-and-see approach was NOT associated with higher adverse outcomes in observational data</li>
            </ul>
          </div>
          <div style="margin-top:0.5rem; padding:0.75rem; background:#fef8ee; border-radius:var(--radius); border:1px solid #fbd38d; font-size:0.82rem;">
            <strong style="color:#9a5a00;">If HIGH-RISK features present AND bleeding risk acceptable:</strong>
            <ul style="margin-top:0.25rem;">
              <li>Anticoagulation (Rec 7a)</li>
              <li>If treatment needed: anticoagulation ALONE preferred over thrombolysis (Rec 8)</li>
              <li>Reserve thrombolysis for exceptional cases with haemodynamic compromise or failure of anticoagulation</li>
            </ul>
          </div>
        </div>
      </div>

      <!-- Situation 4: CVAD Removal Timing -->
      <div class="situation-card" id="sit4">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>4. CVAD Removal Timing ‚Äî Decision Algorithm</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <table class="data-table">
            <thead><tr><th>Step</th><th>Question</th><th>Action</th><th>Source</th></tr></thead>
            <tbody>
              <tr><td>1</td><td>Does patient still require venous access? Is CVAD functioning?</td><td>YES ‚Üí Keep CVAD; continue anticoagulation with CVAD in situ</td><td>2018 Rec 9 ‚Äî conditional</td></tr>
              <tr><td>2</td><td>Is CVAD nonfunctioning OR no longer needed?</td><td>YES ‚Üí Remove CVAD</td><td>2018 Rec 10 ‚Äî STRONG</td></tr>
              <tr><td>3</td><td>Timing of removal: immediate vs delayed?</td><td>Either acceptable (Rec 16)</td><td>2024 Rec 16 ‚Äî ‚äï‚äï‚óã‚óã</td></tr>
              <tr><td>4</td><td>Large thrombotic burden OR right-to-left cardiac shunt?</td><td>YES ‚Üí Anticoagulate for a few days before removal to reduce embolisation risk</td><td>2024 Rec 16 remarks</td></tr>
              <tr><td>5</td><td>Worsening despite anticoagulation, CVAD still needed?</td><td>Individualise: consider removal or no removal</td><td>2018 Rec 12 ‚Äî conditional</td></tr>
            </tbody>
          </table>
        </div>
      </div>

      <!-- Situation 5: Clinically Unsuspected VTE -->
      <div class="situation-card" id="sit5">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>5. Clinically Unsuspected VTE ‚Äî Key Principles</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <ul style="font-size:0.82rem; line-height:1.6;">
            <li>No routine screening for clinically unsuspected VTE is recommended</li>
            <li>If detected incidentally: decision to treat or not treat must be <strong>individualised</strong> (Rec 2)</li>
            <li>Neither treat nor no-treat is universally recommended ‚Äî "either/or" conditional recommendation</li>
            <li>Natural history: lower risk of acute and long-term sequelae than symptomatic VTE, especially in certain subpopulations</li>
          </ul>
          <p style="font-size:0.82rem; font-weight:700; margin:0.5rem 0 0.25rem;">Subpopulations where anticoagulation benefit is particularly uncertain or risk may be higher:</p>
          <ul style="font-size:0.82rem; line-height:1.5;">
            <li>Neonates with CVAD-related VTE</li>
            <li>Critically ill neonates</li>
            <li>Patients with cardiac disease</li>
            <li>Patients who have experienced trauma</li>
          </ul>
          <div class="callout info">
            <span class="callout-icon">‚Ñπ</span>
            <div>Use shared decision-making with patient/family. If not treating: arrange follow-up monitoring for thrombus extension or development of symptoms.</div>
          </div>
        </div>
      </div>

      <!-- Situation 6: Provoked VTE 6-Week Eligibility -->
      <div class="situation-card" id="sit6">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>6. Provoked VTE ‚Äî Kids-DOTT 6-Week Eligibility Checklist</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <div class="callout info">
            <span class="callout-icon">‚Ñπ</span>
            <div>All criteria must be met for 6-week treatment to be appropriate. Any single exclusion criterion directs towards 3 months of anticoagulation.</div>
          </div>
          <p style="font-size:0.82rem; font-weight:700; margin:0.75rem 0 0.25rem; color:var(--clr-success);">INCLUDE (must be present):</p>
          <ul class="checklist" style="margin-bottom:0.5rem;">
            <li class="check">First episode of provoked VTE</li>
          </ul>
          <p style="font-size:0.82rem; font-weight:700; margin:0.5rem 0 0.25rem; color:var(--clr-accent);">EXCLUDE (must ALL be absent):</p>
          <ul class="checklist">
            <li class="cross">PE</li>
            <li class="cross">Recurrent VTE</li>
            <li class="cross">Persistent occlusive thrombus at 6-week imaging</li>
            <li class="cross">Cancer-associated thrombosis</li>
            <li class="cross">Positive antiphospholipid antibodies (APA) at 6 weeks (re-test if initially elevated)</li>
            <li class="cross">Major thrombophilia</li>
            <li class="cross">Ongoing VTE risk factors</li>
            <li class="cross">Active cancer, SLE, proximal PE, or requiring thrombolysis (Kids-DOTT exclusions)</li>
          </ul>
          <p style="font-size:0.78rem; color:#666; margin-top:0.5rem;"><em>If ANY exclusion is met ‚Üí 3 months anticoagulation. For persistent provoking risk factors ‚Üí longer duration may be considered.</em></p>
          <p style="font-size:0.78rem; color:#666;">Most common provoking factors in Kids-DOTT: CVAD (52%), infection (34%), surgery/trauma (20%)</p>
        </div>
      </div>

      <!-- Situation 7: Neonatal RVT -->
      <div class="situation-card" id="sit7">
        <div class="situation-header" onclick="toggleSituation(this)">
          <span>7. Neonatal RVT ‚Äî Laterality and Treatment Algorithm</span>
          <span class="situation-chevron">‚ñº</span>
        </div>
        <div class="situation-body">
          <table class="data-table">
            <thead><tr><th>RVT Type</th><th>Classification</th><th>Treatment</th><th>Recommendation</th></tr></thead>
            <tbody>
              <tr><td>Unilateral RVT</td><td>Non-life-threatening</td><td>Anticoagulation ALONE ‚Äî STRONG AGAINST thrombolysis</td><td>Rec 10a ‚Äî STRONG</td></tr>
              <tr><td>Unilateral RVT + IVC extension</td><td>Non-life-threatening</td><td>Anticoagulation ALONE ‚Äî STRONG AGAINST thrombolysis</td><td>Rec 10a ‚Äî STRONG</td></tr>
              <tr><td>Bilateral RVT</td><td>Life-threatening</td><td>Thrombolysis ‚Üí Anticoagulation</td><td>Rec 10b ‚Äî Conditional</td></tr>
            </tbody>
          </table>
          <p style="font-size:0.82rem; font-weight:700; margin:0.75rem 0 0.25rem;">Factors affecting bleeding risk in neonatal RVT:</p>
          <ul style="font-size:0.82rem; line-height:1.5;">
            <li>Gestational age (premature neonates: much higher bleeding risk)</li>
            <li>Presence of intraventricular haemorrhage (IVH) ‚Äî major contraindication to thrombolysis</li>
            <li>Underlying comorbidities</li>
            <li>Degree of thrombocytopenia</li>
            <li>Severity of disease</li>
          </ul>
          <div class="callout success">
            <span class="callout-icon">‚úì</span>
            <div><strong>Rec 10a is the ONLY STRONG recommendation in the entire guideline</strong> ‚Äî strong recommendation AGAINST thrombolysis for non-life-threatening neonatal RVT. Use anticoagulation alone.</div>
          </div>
          <p style="font-size:0.82rem; margin-top:0.5rem;"><strong>Long-term monitoring for all neonatal RVT:</strong> Blood pressure, renal function, kidney size/atrophy. Paediatric nephrology input recommended.</p>
        </div>
      </div>

    </section>

    <!-- TABLE 2 ‚Äî 2018 RECS NOT ADDRESSED IN 2024 -->
    <section id="table2" class="page-section">
      <h2 class="section-title"><span class="section-icon">üìã</span> 2018 Recommendations Not Addressed in This 2024 Update</h2>
      <p style="font-size:0.82rem; color:#555; margin-bottom:1rem;">The following recommendations from the 2018 ASH guidelines were reviewed but not updated in this 2024 publication. They remain valid from the 2018 guidelines.</p>

      <div class="table2-group">
        <div class="table2-group-header">Thrombectomy and IVC Filters</div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 6 ‚Äî Thrombectomy for Symptomatic DVT or PE</div>
          <p>Suggests AGAINST thrombectomy followed by anticoagulation; rather use anticoagulation alone in paediatric patients with symptomatic DVT or PE (conditional, very low certainty).</p>
          <div class="remarks">Remarks: Panel recognised cardiovascular compromise cases are rare and not without risk; catheter-directed thrombectomy could not be adequately assessed in available data.</div>
        </div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 7 ‚Äî IVC Filters</div>
          <p>Suggests AGAINST using IVC filter; rather use anticoagulation alone in paediatric patients with symptomatic DVT or PE (conditional, very low certainty).</p>
          <div class="remarks">Remarks: IVC filters should be temporary with clear plan for removal; absolute contraindication to anticoagulation or failed adequate anticoagulation in whom filter might reduce embolic risk; not feasible to place IVC filters in children with weight &lt;10 kg.</div>
        </div>
      </div>

      <div class="table2-group">
        <div class="table2-group-header">Antithrombin (AT) Replacement Therapy</div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 8a ‚Äî AT Replacement: Against Routine Use</div>
          <p>Suggests AGAINST AT replacement therapy in addition to standard anticoagulation; rather use standard anticoagulation alone in paediatric patients with DVT/CSVT/PE (conditional, very low certainty).</p>
          <div class="remarks">Remarks: AT use increased dramatically; limited evidence of clinical benefit; perhaps evidence of harm.</div>
        </div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 8b ‚Äî AT Replacement: For Specific Failure Scenarios</div>
          <p>Suggests AT replacement therapy in addition to standard anticoagulation rather than standard anticoagulation alone in paediatric patients with DVT/CSVT/PE who have failed to respond clinically to standard anticoagulation AND in whom subsequent measurement reveals low AT concentrations based on age-appropriate reference ranges (conditional, very low certainty).</p>
          <div class="remarks">Remarks: Certain subgroups may justify AT use ‚Äî documented inherited AT deficiency, children during asparaginase therapy, nephrotic syndrome, after liver transplant, neonates, and in DIC. AT would be commenced if there is continuous thrombus growth and/or failure of clinical response despite adequate anticoagulation.</div>
        </div>
      </div>

      <div class="table2-group">
        <div class="table2-group-header">CVAD-Related Thrombosis (2018 Recommendations)</div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 9 ‚Äî Functioning CVAD, Still Required: No Removal</div>
          <p>Suggests NO removal rather than removal of a functioning CVAD in paediatric patients with symptomatic CVAD-related thrombosis who continue to require venous access (conditional, very low certainty).</p>
        </div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 10 ‚Äî Nonfunctioning or Unneeded CVAD: REMOVE (STRONG)</div>
          <p>RECOMMENDS removal rather than no removal of a nonfunctioning or unneeded CVAD in paediatric patients with symptomatic CVAD-related thrombosis (<strong>STRONG recommendation</strong>, very low certainty).</p>
        </div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 12 ‚Äî Worsening Despite Anticoagulation, CVAD Still Required: Individualise</div>
          <p>Suggests either removal or no removal of a functioning CVAD in paediatric patients with symptomatic CVAD-related thrombosis with worsening signs or symptoms despite anticoagulation who continue to require venous access (conditional, very low certainty).</p>
        </div>
      </div>

      <div class="table2-group">
        <div class="table2-group-header">LMWH vs VKAs</div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 13 ‚Äî LMWH vs VKA: Either</div>
          <p>Suggests using either LMWH or VKAs in paediatric patients with symptomatic DVT or PE (conditional, very low certainty).</p>
          <div class="remarks">Decision based on: (1) patient values and preferences; (2) health services resources; (3) infrastructure and support; (4) underlying condition, comorbidities, and other medications. Note: 2024 update now recommends DOACs over SOC ‚Äî this 2018 rec applies when DOACs are not appropriate or available.</div>
        </div>
      </div>

      <div class="table2-group">
        <div class="table2-group-header">Purpura Fulminans due to Homozygous Protein C Deficiency</div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 24 ‚Äî Protein C Replacement over Anticoagulation Alone</div>
          <p>Suggests protein C replacement rather than anticoagulation alone in paediatric patients with congenital purpura fulminans due to homozygous protein C deficiency (conditional, very low certainty).</p>
        </div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 25 ‚Äî Anticoagulation + Protein C Replacement</div>
          <p>Suggests anticoagulation plus protein C replacement rather than anticoagulation alone in paediatric patients with congenital purpura fulminans due to homozygous protein C deficiency (conditional, very low certainty).</p>
        </div>
        <div class="table2-item">
          <div class="table2-rec-num">2018 Rec 26 ‚Äî Liver Transplantation vs Continued Medical Management</div>
          <p>Suggests using either liver transplantation or no liver transplantation (anticoagulation or protein C replacement) in paediatric patients with congenital purpura fulminans due to homozygous protein C deficiency (conditional, very low certainty).</p>
        </div>
      </div>
    </section>


    <!-- EVIDENCE AND KEY TRIALS SECTION -->
    <section id="evidence" class="page-section">
      <h2 class="section-title"><span class="section-icon">üî¨</span> Evidence &amp; Key Trials</h2>

      <h3 style="font-size:0.9rem; font-weight:700; color:var(--clr-primary); margin-bottom:0.75rem;">Key Outcomes of Interest (All PICO Questions)</h3>
      <div style="display:flex; flex-wrap:wrap; gap:0.4rem; margin-bottom:1.25rem;">
        <span style="background:#e8f4ff; border:1px solid #bfdbfe; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1e3a5f;">Mortality</span>
        <span style="background:#e8f4ff; border:1px solid #bfdbfe; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1e3a5f;">VTE Resolution</span>
        <span style="background:#e8f4ff; border:1px solid #bfdbfe; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1e3a5f;">VTE Recurrence</span>
        <span style="background:#e8f4ff; border:1px solid #bfdbfe; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1e3a5f;">Thrombus Extension</span>
        <span style="background:#fde8e8; border:1px solid #f5c6c6; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#7b1c1c;">Major Bleeding</span>
        <span style="background:#fde8e8; border:1px solid #f5c6c6; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#7b1c1c;">CRNMB</span>
        <span style="background:#fef3e2; border:1px solid #fbd38d; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#7d4e00;">Post-Thrombotic Syndrome (PTS)</span>
        <span style="background:#fef3e2; border:1px solid #fbd38d; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#7d4e00;">HITT</span>
        <span style="background:#f5f0fa; border:1px solid #d8b4fe; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#4a1772;">Neurological Outcome (CSVT)</span>
        <span style="background:#f5f0fa; border:1px solid #d8b4fe; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#4a1772;">Cerebral Infarction (CSVT/RAT)</span>
        <span style="background:#f0faf4; border:1px solid #a8ddb8; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1a5c35;">Kidney Function (RVT)</span>
        <span style="background:#f0faf4; border:1px solid #a8ddb8; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1a5c35;">Portal Hypertension (PVT)</span>
        <span style="background:#f0faf4; border:1px solid #a8ddb8; border-radius:12px; padding:0.2rem 0.6rem; font-size:0.73rem; color:#1a5c35;">Paradoxical Embolism (CVAD)</span>
      </div>

      <div class="trial-card">
        <div class="trial-name">EINSTEIN-Junior</div>
        <div class="trial-meta">Rivaroxaban vs SOC (LMWH or VKA) in Paediatric VTE ¬∑ n=500 ¬∑ Randomised Controlled Trial</div>
        <p><strong>Population:</strong> Birth &gt;37 weeks gestational age to age 17 years with confirmed VTE. <strong>Excluded:</strong> Age &lt;6 months, low birth weight, severe liver or renal impairment.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> Small benefit in reduced thrombus recurrence rate and improved thrombus resolution with rivaroxaban. Major bleeding reduced vs SOC. Clinically relevant non-major bleeding (CRNMB) increased. Heavier menstrual bleeding reported in adolescent females. 22/651 (3.4%) recurrent VTE; 10/651 (1.5%) radiological thrombus extension; no patient had symptomatic PE.</p>
        <p style="margin-top:0.35rem;"><strong>Limitation:</strong> Eligibility criteria restricted enrolment ‚Äî results not generalisable to all paediatric patients; small number of outcome events; 3‚Äì6 month evaluation may underestimate PTS and long-term outcomes.</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendations 1, 17, 18, 20</p>
      </div>

      <div class="trial-card">
        <div class="trial-name">DIVERSITY</div>
        <div class="trial-meta">Dabigatran vs SOC in Paediatric VTE ¬∑ n=267 ¬∑ Randomised Controlled Trial</div>
        <p><strong>Population:</strong> Birth &gt;37 weeks gestational age to age &lt;18 years with confirmed VTE. <strong>Excluded:</strong> Age &lt;2 years with low body weight, severe liver or renal impairment.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> Small benefit: reduced thrombus recurrence and improved thrombus resolution. Fewer major bleeds with dabigatran. CRNMB equivalent to SOC. Gastrointestinal side effects increased. Monitoring and dose adjustment was required per trial protocol ‚Äî concern raised about routine use per current approvals which do NOT require monitoring.</p>
        <p style="margin-top:0.35rem;"><strong>Limitation:</strong> Monitoring concern; small number of outcome events; exclusion criteria limit generalisability.</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendations 1, 17, 19, 20</p>
      </div>

      <div class="trial-card">
        <div class="trial-name">Kids-DOTT</div>
        <div class="trial-meta">Duration of Anticoagulation in Paediatric Provoked VTE ¬∑ n=417 randomised; 297 per-protocol analysis ¬∑ Randomised Controlled Trial</div>
        <p><strong>Design:</strong> First RCT evaluating duration of anticoagulation in paediatric patients with first episode of provoked VTE. 6 weeks vs 3 months.</p>
        <p style="margin-top:0.35rem;"><strong>Population:</strong> First episode provoked VTE. Most common provoking factor: CVAD (52%), infection (34%), surgery/trauma (20%). &gt;85% received LMWH.</p>
        <p style="margin-top:0.35rem;"><strong>Excluded:</strong> Active cancer, major thrombophilia, SLE, proximal PE, patients requiring thrombolysis. APA positive at 6 weeks excluded from randomisation.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> Demonstrated non-inferiority of 6-week vs 3-month anticoagulation for recurrent VTE and clinically relevant bleeding. Symptomatic recurrent VTE: 1/154 (0.6%) 6-week vs 2/143 (1.4%) 3-month. No difference in mortality (4/206 [1.9%] vs 4/206 [1.9%]).</p>
        <p style="margin-top:0.35rem;"><strong>Limitation:</strong> Stringent eligibility criteria ‚Äî many paediatric patients with provoked VTE were excluded. Cannot be extrapolated beyond its specific inclusion criteria. Not powered for small differences in recurrence.</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendation 3</p>
      </div>

      <div class="trial-card">
        <div class="trial-name">NEOCLOT Study</div>
        <div class="trial-meta">Neonates/Infants ‚â§6 months with CVAD-Associated VTE ¬∑ n=115 ¬∑ Prospective Multicenter Observational Study</div>
        <p><strong>Population:</strong> Neonates and infants ‚â§6 months with CVAD-associated VTE treated per national consensus guideline.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> 21/24 (87.5%) receiving anticoagulation had thrombus resolution vs 11/13 (84.6%) not; 8/25 (32.1%) infants not receiving anticoagulation had radiological thrombus extension. Major bleeding: 2/33 (6.1%) and CRNMB 1/33 (3.0%) receiving anticoagulation; 0 not receiving. Informs exception to Rec 1 for neonatal CVAD-associated VTE.</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendation 1</p>
      </div>

      <div class="trial-card">
        <div class="trial-name">Retrospective Multicenter Observational Study (Neonates/Infants/Children &lt;2 years)</div>
        <div class="trial-meta">n=346 ¬∑ Retrospective Multicenter Observational</div>
        <p><strong>Population:</strong> Neonates, infants, children &lt;2 years with VTE.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> 7/223 (3.1%) receiving anticoagulation had recurrent VTE vs 4/47 (8.5%) without anticoagulation (RR 0.38; 95% CI 0.12‚Äì1.3).</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendation 1</p>
      </div>

      <div class="trial-card">
        <div class="trial-name">Single-Centre Retrospective ‚Äî Trauma-Associated VTE</div>
        <div class="trial-meta">n=753 ¬∑ Single-Centre Retrospective</div>
        <p><strong>Population:</strong> Paediatric patients &lt;18 years with trauma-associated VTE.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> Mortality 1/31 (3.2%) anticoagulation vs 0/10 (0%) no anticoagulation; thrombus resolution 13/31 (41.9%) vs 6/10 (60.0%) (RR 0.69; 95% CI 0.36‚Äì1.34). No clear benefit of anticoagulation in trauma-associated paediatric VTE. Informs exception in Rec 1.</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendation 1</p>
      </div>

      <div class="trial-card">
        <div class="trial-name">Adult ASH 2020 Meta-Analysis ‚Äî Indefinite vs Finite Anticoagulation</div>
        <div class="trial-meta">Adult Population ¬∑ Meta-analysis ¬∑ High Certainty Evidence (in Adults)</div>
        <p><strong>Design:</strong> Meta-analysis used to inform adult ASH 2020 guidelines on unprovoked VTE treatment duration.</p>
        <p style="margin-top:0.35rem;"><strong>Key results:</strong> Indefinite anticoagulation significantly reduces PE (RR 0.29; 95% CI 0.15‚Äì0.56) and DVT (RR 0.20; 95% CI 0.12‚Äì0.34) ‚Äî high certainty in adults. Increases major bleeding (RR 2.17; 95% CI 1.20‚Äì3.35 ‚Äî high certainty).</p>
        <p style="margin-top:0.35rem;"><strong>Limitation:</strong> Adult data only ‚Äî extrapolation to paediatric patients is problematic. Impact on QOL and development in younger patients not reflected in adult data. Certainty for paediatric patients: very low.</p>
        <p style="margin-top:0.35rem;"><strong>Informs:</strong> Recommendation 4</p>
      </div>
    </section>

    <!-- DISCLAIMER -->
    <section id="disclaimer" class="page-section">
      <div id="disclaimer">
        <span class="disclaimer-icon">‚öï</span>
        <strong>Educational Summary Only.</strong> This page summarises the ASH/ISTH 2024 Updated Guidelines for Treatment of VTE in Paediatric Patients (<em>Blood Advances</em> 2025;9:2587‚Äì2606; DOI: 10.1182/bloodadvances.2024015328). It does not replace local protocols, Summary of Product Characteristics (SPCs), or specialist advice. Always consult a paediatric haematologist or haematology-trained paediatrician for individual patient decisions.
        <br><br>
        <strong>Numeric dosing information is NOT included</strong> as it was not present in the provided guideline text ‚Äî refer to the original publication, drug SPCs, local formularies, and the British National Formulary for Children (BNFc) or equivalent local resources.
        <br><br>
        All recommendations reflect those in the published guideline. Readers should refer to the full published guideline for complete methodology, evidence tables, and EtD frameworks. Recommendations may change as new evidence emerges. This summary was prepared for educational purposes and does not constitute individual medical or pharmaceutical advice. The preparer accepts no liability for clinical decisions made on the basis of this summary.
        <br><br>
        <strong>Guideline citation:</strong> Monagle P et al. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. <em>Blood Advances</em>. 2025;9(10):2587‚Äì2606. https://doi.org/10.1182/bloodadvances.2024015328
        <br><br>
        <div style="margin-top:1rem; padding:1rem 1.25rem; background:linear-gradient(135deg,#0f2d52,#1a3f6f); border-radius:var(--radius); color:#fff; display:flex; align-items:center; gap:1rem; flex-wrap:wrap;">
          <span style="font-size:1.75rem; flex-shrink:0;">ü©∏</span>
          <div style="flex:1; min-width:200px;">
            <div style="font-size:0.65rem; font-weight:800; text-transform:uppercase; letter-spacing:0.1em; opacity:0.7; margin-bottom:0.2rem;">Conceived &amp; Created by</div>
            <div style="font-size:1rem; font-weight:700; letter-spacing:-0.01em;">Dr Abdul Mannan</div>
            <div style="font-size:0.78rem; opacity:0.85; margin-top:0.15rem;">FRCPath ¬∑ FCPS ¬∑ Consultant Haematologist</div>
            <div style="font-size:0.75rem; opacity:0.7; margin-top:0.35rem; display:flex; align-items:center; gap:0.5rem; flex-wrap:wrap;">
              <span>Bloodü©∏Doctor</span>
              <span style="opacity:0.4;">|</span>
              <a href="mailto:blooddoctor.co@gmail.com" style="color:#93c5fd; text-decoration:none;">blooddoctor.co@gmail.com</a>
            </div>
          </div>
        </div>
      </div>
    </section>

  </main>
</div><!-- end layout -->

<!-- BACK TO TOP FAB -->
<button id="back-to-top" aria-label="Back to top">‚Üë</button>

<script>
/* ===== CARD TOGGLE ===== */
function toggleCard(header) {
  const card = header.closest('.rec-card');
  const isOpen = card.classList.toggle('open');
  header.setAttribute('aria-expanded', isOpen);
}

/* ===== PANEL TABS ===== */
function switchTab(btn, targetId) {
  const card = btn.closest('.rec-card');
  card.querySelectorAll('.panel-tab').forEach(t => t.classList.remove('active'));
  btn.classList.add('active');
  card.querySelectorAll('.panel-content').forEach(p => p.classList.remove('active'));
  const target = document.getElementById(targetId);
  if (target) target.classList.add('active');
}

/* ===== SITUATION TOGGLE ===== */
function toggleSituation(header) {
  const card = header.closest('.situation-card');
  card.classList.toggle('open');
}

/* ===== HAMBURGER / SIDEBAR ===== */
const hamburger = document.getElementById('hamburger-btn');
const sidebar = document.getElementById('sidebar');
const backdrop = document.getElementById('sidebar-backdrop');

function openSidebar() {
  sidebar.classList.add('open');
  backdrop.classList.add('open');
  backdrop.removeAttribute('aria-hidden');
  hamburger.setAttribute('aria-expanded', 'true');
  hamburger.textContent = '‚úï';
}

function closeSidebar() {
  sidebar.classList.remove('open');
  backdrop.classList.remove('open');
  backdrop.setAttribute('aria-hidden', 'true');
  hamburger.setAttribute('aria-expanded', 'false');
  hamburger.textContent = '‚ò∞';
}

hamburger.addEventListener('click', () => {
  if (sidebar.classList.contains('open')) {
    closeSidebar();
  } else {
    openSidebar();
  }
});

backdrop.addEventListener('click', closeSidebar);

// Close sidebar on TOC link click (mobile)
sidebar.querySelectorAll('.toc-link').forEach(link => {
  link.addEventListener('click', () => {
    if (window.innerWidth < 768) closeSidebar();
  });
});

/* ===== TOGGLE BAR ‚Äî Smart Auto-Hide on Scroll ===== */
const toggleBar = document.getElementById('toggle-bar');
const togglePill = document.getElementById('toggle-bar-pill');
let lastScrollY = window.scrollY;
let toggleBarVisible = true;
let scrollTicking = false;

function showToggleBar() {
  toggleBar.classList.remove('hidden');
  if (togglePill) togglePill.classList.remove('visible');
  toggleBarVisible = true;
}

function hideToggleBar() {
  toggleBar.classList.add('hidden');
  if (togglePill) togglePill.classList.add('visible');
  toggleBarVisible = false;
}

window.addEventListener('scroll', () => {
  if (!scrollTicking) {
    requestAnimationFrame(() => {
      const currentScrollY = window.scrollY;
      const delta = currentScrollY - lastScrollY;

      // Only trigger after scrolling past 80px from top
      if (currentScrollY < 80) {
        showToggleBar();
      } else if (delta > 8 && toggleBarVisible) {
        // Scrolling DOWN more than 8px ‚Äî hide
        hideToggleBar();
      } else if (delta < -5 && !toggleBarVisible) {
        // Scrolling UP more than 5px ‚Äî show
        showToggleBar();
      }

      lastScrollY = currentScrollY;
      scrollTicking = false;
    });
    scrollTicking = true;
  }
}, { passive: true });

// Pill click ‚Äî manually show toggle bar
if (togglePill) {
  togglePill.addEventListener('click', () => {
    showToggleBar();
  });
}

/* ===== VIEW MODE BUTTONS ===== */
const main = document.getElementById('main-content');
const btnEvidence = document.getElementById('btn-evidence');
const btnImplementation = document.getElementById('btn-implementation');
const btnQuickview = document.getElementById('btn-quickview');

/* Helper: deactivate all view modes and restore card states */
function clearAllViewModes() {
  main.classList.remove('show-evidence', 'show-implementation', 'quick-view');
  [btnEvidence, btnImplementation, btnQuickview].forEach(b => {
    b.classList.remove('active');
    b.setAttribute('aria-pressed', 'false');
  });
}

btnEvidence.addEventListener('click', () => {
  const wasActive = btnEvidence.classList.contains('active');
  clearAllViewModes();
  if (!wasActive) {
    main.classList.add('show-evidence');
    btnEvidence.classList.add('active');
    btnEvidence.setAttribute('aria-pressed', 'true');
    // Expand all cards so evidence panels are visible
    document.querySelectorAll('.rec-card').forEach(c => c.classList.add('open'));
  }
  // If was active, we just cleared ‚Äî cards stay open for user to browse
});

btnImplementation.addEventListener('click', () => {
  const wasActive = btnImplementation.classList.contains('active');
  clearAllViewModes();
  if (!wasActive) {
    main.classList.add('show-implementation');
    btnImplementation.classList.add('active');
    btnImplementation.setAttribute('aria-pressed', 'true');
    // Expand all cards so impl panels are visible
    document.querySelectorAll('.rec-card').forEach(c => c.classList.add('open'));
  }
});

btnQuickview.addEventListener('click', () => {
  const wasActive = btnQuickview.classList.contains('active');
  clearAllViewModes();
  if (!wasActive) {
    main.classList.add('quick-view');
    btnQuickview.classList.add('active');
    btnQuickview.setAttribute('aria-pressed', 'true');
    // Expand all cards so quick-content is visible
    document.querySelectorAll('.rec-card').forEach(c => c.classList.add('open'));
  }
});

/* Search removed */

/* ===== DARK / LIGHT MODE ===== */
const themeToggleBtn = document.getElementById('theme-toggle-btn');
const htmlEl = document.documentElement;

// Load saved theme preference
const savedTheme = localStorage.getItem('vte-theme') || 'light';
if (savedTheme === 'dark') {
  htmlEl.setAttribute('data-theme', 'dark');
  if (themeToggleBtn) themeToggleBtn.textContent = '‚òÄÔ∏è';
}

if (themeToggleBtn) {
  themeToggleBtn.addEventListener('click', () => {
    const isDark = htmlEl.getAttribute('data-theme') === 'dark';
    if (isDark) {
      htmlEl.removeAttribute('data-theme');
      themeToggleBtn.textContent = 'üåô';
      localStorage.setItem('vte-theme', 'light');
    } else {
      htmlEl.setAttribute('data-theme', 'dark');
      themeToggleBtn.textContent = '‚òÄÔ∏è';
      localStorage.setItem('vte-theme', 'dark');
    }
  });
}

/* ===== BACK TO TOP ===== */
const backToTop = document.getElementById('back-to-top');
window.addEventListener('scroll', () => {
  if (window.scrollY > 400) {
    backToTop.classList.add('visible');
  } else {
    backToTop.classList.remove('visible');
  }
}, { passive: true });
backToTop.addEventListener('click', () => {
  window.scrollTo({ top: 0, behavior: 'smooth' });
});

/* ===== SIDEBAR TOC: Active Section Highlighting ===== */
const tocLinks = document.querySelectorAll('.toc-link');

const sectionIds = Array.from(tocLinks)
  .map(l => l.getAttribute('href'))
  .filter(h => h && h.startsWith('#'))
  .map(h => h.slice(1));

const observer = new IntersectionObserver((entries) => {
  entries.forEach(entry => {
    if (entry.isIntersecting) {
      const id = entry.target.id;
      tocLinks.forEach(link => {
        link.classList.remove('active');
        if (link.getAttribute('href') === '#' + id) {
          link.classList.add('active');
        }
      });
    }
  });
}, {
  rootMargin: '-20% 0% -75% 0%',
  threshold: 0
});

sectionIds.forEach(id => {
  const el = document.getElementById(id);
  if (el) observer.observe(el);
});

/* ===== KEYBOARD: ESC closes sidebar ===== */
document.addEventListener('keydown', (e) => {
  if (e.key === 'Escape') {
    closeSidebar();
  }
});
</script>

</body>
</html>
